{"content":"<li class=\"n-box-item date-title\" data-end=\"1507089599\" data-start=\"1507003200\" data-txt=\"Monday, December 23, 2019\">Tuesday, October  3, 2017</li><li class=\"n-box-item sa-box-item\" data-id=\"3299176\" data-ts=\"1507069139\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/I\" target=\"_blank\">I</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3299176-intelsat-jumps-11-rbc-praises-intel-c-band-sharing\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Intelsat jumps 11% as RBC praises Intel C-band sharing</a></h4><ul>   <li>Intelsat (<a href=\"http://seekingalpha.com/symbol/I\" target=\"_blank\">I</a> <font color='green'>+11%</font>) vaulted and is <font color='green'>up 0.7%</font> after hours now after a positive call from RBC on its plan with Intel (<a href=\"http://seekingalpha.com/symbol/INTC\" target=\"_blank\">INTC</a> <font color='green'>+0.9%</font>) to share C-band spectrum for use in 5G networking.</li>    <li>The two companies jointly submitted a plan to the FCC to share that spectrum in what could be a \"gold mine,\" says RBC's Wilton Fry.</li>    <li>Intelsat has about 500 MHz of potentially usable spectrum, in the 4 GHz-8 GHz satellite range, that doesn't suffer rain fade.</li>    <li>That spectrum is underused, Fry suggests, and if the deal is approved and the spectrum is monetized it could be worth $14/share. (Intelsat closed at $5.37 today.)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3299176\" data-linked=\"Intelsat jumps 11% as RBC praises Intel C-band sharing\" data-tweet=\"$I $I $INTC - Intelsat jumps 11% as RBC praises Intel C-band sharing https://seekingalpha.com/news/3299176-intelsat-jumps-11-rbc-praises-intel-c-band-sharing?source=tweet\" data-url=\"https://seekingalpha.com/news/3299176-intelsat-jumps-11-rbc-praises-intel-c-band-sharing\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:18 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3299171\" data-ts=\"1507066700\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3299171-after-hours-gainers-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">After Hours Gainers / Losers</a></h4><ul>     <li><b>Top gainers, as of 5.25 p.m.:</b> <a href='https://seekingalpha.com/symbol/CTMX' title='CytomX Therapeutics'>CTMX</a> <font color='green'>+32.7%</font>. <a href='https://seekingalpha.com/symbol/FCEL' title='FuelCell Energy, Inc.'>FCEL</a> <font color='green'>+6.4%</font>. <a href='https://seekingalpha.com/symbol/I' title='Intelsat SA'>I</a> <font color='green'>+5.2%</font>. <a href='https://seekingalpha.com/symbol/BW' title='Babcock & Wilcox Enterprises, Inc.'>BW</a> <font color='green'>+3.2%</font>. <a href='https://seekingalpha.com/symbol/GBT' title='Global Blood Therapeutics'>GBT</a> <font color='green'>+2.7%</font>.</li><li><b>Top losers, as of 5.25p.m.:</b> <a href='https://seekingalpha.com/symbol/ODP' title='Office Depot Inc.'>ODP</a> <font color='red'>-8.9%</font>. <a href='https://seekingalpha.com/symbol/RIGL' title='Rigel Pharmaceuticals, Inc.'>RIGL</a> <font color='red'>-7.7%</font>. <a href='https://seekingalpha.com/symbol/NLNK' title='NewLink Genetics Corporation'>NLNK</a> <font color='red'>-6.5%</font>. <a href='https://seekingalpha.com/symbol/VSAR-OLD' title='Versartis, Inc.'>VSAR-OLD</a> <font color='red'>-3.8%</font>. <a href='https://seekingalpha.com/symbol/VEON' title='VEON Ltd. ADS'>VEON</a> <font color='red'>-2.4%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3299171\" data-linked=\"After Hours Gainers / Losers\" data-tweet=\"$CTMX $FCEL $I - After Hours Gainers / Losers https://seekingalpha.com/news/3299171-after-hours-gainers-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3299171-after-hours-gainers-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:38 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3299167\" data-ts=\"1507065313\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/IDT\" target=\"_blank\">IDT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3299167-idt-q4-profits-decline-though-revenues-get-boost\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">IDT Q4 profits decline though revenues get a boost</a></h4><ul>   <li>IDT (<a href=\"http://seekingalpha.com/symbol/IDT\" target=\"_blank\">IDT</a> <font color='green'>+4%</font>) boosted revenues but saw EBITDA fall 14% in <a href=\"https://seekingalpha.com/news/3299158-idt-corporation-reports-q4-results\" target=\"_blank\">Q4 results</a> as it continued attempts to divest noncore assets.</li>    <li>The company's still working to spin off assets including real estate and its interests in Rafael Pharmaceuticals, but \"we continued to invest heavily in our growth initiatives including net2phone&rsquo;s unified communications as a service business, National Retail Solutions, BOSS Revolution international money transfer, and the BOSS Revolution mobile service that we expect to launch later this quarter,\" says CEO Shmuel Jonas.</li>    <li>Revenue by segment: Telecom Platform Services, $384.8M (up 7.5%); Unified Communications as a Service, $7.8M (up 11.4%); Consumer Phone Services, $1.3M (down 18.8%); All other, $1.2M (down 14.3%).</li>    <li>TPS revenue by business vertical: Retail communications, $151.4M (down 7.5%); Wholesale Carrier Services, $167.4M (up 20.4%); Payment services, $66M (up 18.9%).</li>    <li><a href=\"http://www.idt.net/ir\" target=\"_blank\">Conference call</a> to come at 5:30 p.m. ET.</li>    <li><a href=\"https://www.sec.gov/Archives/edgar/data/1005731/000121390017010266/f8k100317ex99-1_idtcorp.htm\" target=\"_blank\">Press Release</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3299167\" data-linked=\"IDT Q4 profits decline though revenues get a boost\" data-tweet=\"$IDT $RFL - IDT Q4 profits decline though revenues get a boost https://seekingalpha.com/news/3299167-idt-q4-profits-decline-though-revenues-get-boost?source=tweet\" data-url=\"https://seekingalpha.com/news/3299167-idt-q4-profits-decline-though-revenues-get-boost\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:15 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3299159\" data-ts=\"1507064107\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ODP\" target=\"_blank\">ODP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3299159-office-depot-buying-compucom-for-1b-shares-slump-11\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Office Depot buying Compucom for about $1B; shares slump 11%</a></h4><ul><li>Office Depot (NYSE:<a href='https://seekingalpha.com/symbol/ODP' title='Office Depot Inc.'>ODP</a>) bills the purchase as the first step in a pivot from a traditional office supply retailer to a broader business services and technology products platform.</li><li>\"Technology is the office supply of the future,\" says CEO Gerry Smith.</li><li>The seller is Thomas H. Lee Partners, and part of the consideration will be 45M shares of ODP stock, with the P-E firm owning 8% of Office Depot following the sale.</li><li>Alongside, Office Depot is providing early Q3 numbers, with sales expected to be lower by 7%-8%, and comp sales down 5%-6%. Adjusted operating income is seen at $125M-$135M, and free cash flow from continuing operations of about $200M.</li><li>The purchase is expected to close before year-end.</li><li>Source: <a href=\"https://seekingalpha.com/pr/16958647-office-depot-takes-first-step-strategic-transformation-become-business-services-platform\" target=\"_blank\">Press Release</a></li><li>ODP flat after hours</li><li><strong>Update at 5:21 ET:</strong> Shares are now<font color='red'> lower by 11%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3299159\" data-linked=\"Office Depot buying Compucom for about $1B; shares slump 11%\" data-tweet=\"$ODP - Office Depot buying Compucom for about $1B; shares slump 11% https://seekingalpha.com/news/3299159-office-depot-buying-compucom-for-1b-shares-slump-11?source=tweet\" data-url=\"https://seekingalpha.com/news/3299159-office-depot-buying-compucom-for-1b-shares-slump-11\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:55 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3299153\" data-ts=\"1507063036\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/KR\" target=\"_blank\">KR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3299153-bernstein-weighs-in-on-kroger-ahold-chatter\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Bernstein weighs in on Kroger-Ahold chatter</a></h4><ul><li>Bernstein analyst Bruno Monteyne believes that any deal between Kroger (NYSE:<a href='https://seekingalpha.com/symbol/KR' title='Kroger Co.'>KR</a>) and Ahold (<a href='https://seekingalpha.com/symbol/AHODF' title='Koninklijke Ahold Delhaize N.V.'>OTCQX:AHODF</a>) would have to be <a href=\"https://www-bizjournals-com.cdn.ampproject.org/c/s/www.bizjournals.com/cincinnati/news/2017/10/03/kroger-stock-jumps-amid-acquisition-rumors.amp.html\" target=\"_blank\">structured</a> as a merger of equals.</li><li>Monteyne thinks the $32 deal price being bandied around refers to the valuation of the combined grocery store chains after post-merger synergies kick in.</li><li>Kroger finished up 3% amid speculation on the Ahold interest.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3299064-kroger-perks-m-chatter\" target=\"_blank\">Kroger perks up on M&amp;A chatter</a> (Oct. 3)</li></ul><div class=\"tiny-share-widget\" data-id=\"3299153\" data-linked=\"Bernstein weighs in on Kroger-Ahold chatter\" data-tweet=\"$KR $KR $AHODF - Bernstein weighs in on Kroger-Ahold chatter https://seekingalpha.com/news/3299153-bernstein-weighs-in-on-kroger-ahold-chatter?source=tweet\" data-url=\"https://seekingalpha.com/news/3299153-bernstein-weighs-in-on-kroger-ahold-chatter\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:37 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>45&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3299152\" data-ts=\"1507063022\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RIGL\" target=\"_blank\">RIGL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3299152-rigel-pharma-launches-40m-stock-offering-shares-down-9-after-hours\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Rigel Pharma launches $40M stock offering; shares down 9% after hours</a></h4><ul><li>Rigel Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/RIGL' title='Rigel Pharmaceuticals, Inc.'>RIGL</a>) <a href=\"http://ir.rigel.com/phoenix.zhtml?c=120936&amp;p=irol-newsArticle&amp;ID=2304429\" target=\"_blank\">commences </a>a $40M public offering of common stock. Price, volume and terms have yet to be announced.</li><li>Share are off&nbsp;<font color='red'>9%</font>&nbsp;after hours on increased volume.</li></ul><div class=\"tiny-share-widget\" data-id=\"3299152\" data-linked=\"Rigel Pharma launches $40M stock offering; shares down 9% after hours\" data-tweet=\"$RIGL - Rigel Pharma launches $40M stock offering; shares down 9% after hours https://seekingalpha.com/news/3299152-rigel-pharma-launches-40m-stock-offering-shares-down-9-after-hours?source=tweet\" data-url=\"https://seekingalpha.com/news/3299152-rigel-pharma-launches-40m-stock-offering-shares-down-9-after-hours\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:37 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3299150\" data-ts=\"1507062667\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CTMX\" target=\"_blank\">CTMX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3299150-cytomx-teams-up-amgen-to-develop-egfr-targeting-antibodies-for-cancer\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">CytomX teams up with Amgen to develop EGFR-targeting antibodies for cancer</a></h4><ul><li>CytomX Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/CTMX' title='CytomX Therapeutics'>CTMX</a>) inks a <a href=\"http://www.prnewswire.com/news-releases/amgen-and-cytomx-therapeutics-announce-strategic-collaboration-in-immuno-oncology-300530325.html\" target=\"_blank\">strategic collaboration</a> with Amgen (NASDAQ:<a href='https://seekingalpha.com/symbol/AMGN' title='Amgen Inc.'>AMGN</a>) to co-develop a CytomX Probody T-cell engaging bispecific against the well-validated cancer target Epidermal Growth Factor Receptor &#40;EGFR&#41;.</li><li>Probody T-cell engaging bispecifics are antibody constructs that the company says are capable of directing cytotoxic T cells in tumor microenvironments. In preclinical studies, CytomX's Probody versions of EGFRxCD3 bispecific therapeutics induced tumor regressions and increased the therapeutic window for the target.</li><li>Under the terms of the partnership, the companies will co-develop a Probody T-cell engaging bispecific against EGFRxCD3. CytomX will lead early development with Amgen taking over later development and commercialization. Global late-stage development costs will be shared. Amgen will pay $40M upfront and purchase $20M of CTMX common stock. CytomX will be eligible for up to $455M in milestones plus tiered double-digit royalties on net ex-U.S. sales. It has the option of opting into a profit share in the U.S.</li><li>Amgen also receives exclusive global rights to develop and commercialize up to three additional targets. CytomX will be eligible to receive up to $950M in milestones plus high-single-digit to mid-double-digit royalties on any commercialized products.</li><li>CytomX will host a conference call today at 5:00 pm ET to discuss the deal.</li><li>Shares will resume trading momentarily.</li></ul><div class=\"tiny-share-widget\" data-id=\"3299150\" data-linked=\"CytomX teams up with Amgen to develop EGFR-targeting antibodies for cancer\" data-tweet=\"$CTMX $CTMX $AMGN - CytomX teams up with Amgen to develop EGFR-targeting antibodies for cancer https://seekingalpha.com/news/3299150-cytomx-teams-up-amgen-to-develop-egfr-targeting-antibodies-for-cancer?source=tweet\" data-url=\"https://seekingalpha.com/news/3299150-cytomx-teams-up-amgen-to-develop-egfr-targeting-antibodies-for-cancer\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:31 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3299143\" data-ts=\"1507061438\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NLNK\" target=\"_blank\">NLNK</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3299143-newlink-readies-50m-stock-offering-shares-down-4-after-hours\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">NewLink readies $50M stock offering; shares down 4% after hours</a></h4><ul><li>NewLink Genetics (NASDAQ:<a href='https://seekingalpha.com/symbol/NLNK' title='NewLink Genetics Corporation'>NLNK</a>) <a href=\"https://seekingalpha.com/pr/16958597-newlink-genetics-announces-proposed-public-offering-common-stock\" target=\"_blank\">launches </a>a $50M public offering of common stock. Price, volume and terms have yet to be announced.</li><li>Shares are off&nbsp;<font color='red'>4%</font>&nbsp;after hours.</li></ul><div class=\"tiny-share-widget\" data-id=\"3299143\" data-linked=\"NewLink readies $50M stock offering; shares down 4% after hours\" data-tweet=\"$NLNK - NewLink readies $50M stock offering; shares down 4% after hours https://seekingalpha.com/news/3299143-newlink-readies-50m-stock-offering-shares-down-4-after-hours?source=tweet\" data-url=\"https://seekingalpha.com/news/3299143-newlink-readies-50m-stock-offering-shares-down-4-after-hours\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:10 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3299142\" data-ts=\"1507061207\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CTMX\" target=\"_blank\">CTMX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3299142-cytomx-therapeutics-trading-halted-pending-news\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">CytomX Therapeutics trading halted pending news</a></h4><ul><li>Nasdaq has suspended trading in CytomX Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/CTMX' title='CytomX Therapeutics'>CTMX</a>) pending the release of news.</li></ul><div class=\"tiny-share-widget\" data-id=\"3299142\" data-linked=\"CytomX Therapeutics trading halted pending news\" data-tweet=\"$CTMX - CytomX Therapeutics trading halted pending news https://seekingalpha.com/news/3299142-cytomx-therapeutics-trading-halted-pending-news?source=tweet\" data-url=\"https://seekingalpha.com/news/3299142-cytomx-therapeutics-trading-halted-pending-news\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:06 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3299140\" data-ts=\"1507061050\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MTBC\" target=\"_blank\">MTBC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3299140-medical-transcription-up-big-on-bullish-launch-of-talkehr-shares-up-115\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Medical Transcription up big on bullish launch of talkEHR; shares up 115%</a></h4><ul><li>Nano cap Medical Transcription Billing (<a href='https://seekingalpha.com/symbol/MTBC' title='Medical Transcription Billing'>MTBC</a> <font color='green'>+115.2%</font>) had a huge day on more than 5x higher volume. The catalyst appeared to be a <a href=\"http://www.mtbc.com/about-us/press-room/press_release?id=42492\" target=\"_blank\">press release</a> announcing the successful launch of its next-generation, voice-enabled electronic records solution, talkEHR.</li><li>The company says it is offering talkEHR free of charge to all U.S. healthcare providers who can upgrade to the full-service package, including end-to-end medical billing, for 2.95% of a physician's collections.</li></ul><div class=\"tiny-share-widget\" data-id=\"3299140\" data-linked=\"Medical Transcription up big on bullish launch of talkEHR; shares up 115%\" data-tweet=\"$MTBC - Medical Transcription up big on bullish launch of talkEHR; shares up 115% https://seekingalpha.com/news/3299140-medical-transcription-up-big-on-bullish-launch-of-talkehr-shares-up-115?source=tweet\" data-url=\"https://seekingalpha.com/news/3299140-medical-transcription-up-big-on-bullish-launch-of-talkehr-shares-up-115\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:04 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>10&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3299139\" data-ts=\"1507060721\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GEVO\" target=\"_blank\">GEVO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3299139-gevo-to-supply-jet-fuel-to-virgin-australia\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Gevo to supply jet fuel to Virgin Australia</a></h4><ul>     <li>Gevo (<a href='https://seekingalpha.com/symbol/GEVO' title='Gevo, Inc.'>GEVO</a> <font color='green'>+9.2%</font>) surges nearly 10% on news that it expects to begin later this month <a href=\"https://seekingalpha.com/pr/16957949-gevo-supply-jet-fuel-virgin-australia-brisbane-airport-australia\" target=\"_blank\">supplying its renewable alcohol-to-jet fuel</a> to the Virgin Australia airline.</li>     <li>Virgin Australia will be responsible for coordinating the purchase, supply and blending of alcohol-to-jet fuel into the fuel supply system at the Brisbane Airport in Queensland, Australia.</li>     <li>Gevo also says it is looking to expand its isobutanol production capabilities at its Luverne, Minn., facility to enable larger production volumes of its ATJ; its goal this year is to secure binding supply contracts  for a combination of isobutanol and hydrocarbon products equal to at least 50% of the capacity of the anticipated  expanded Luverne plant.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3299139\" data-linked=\"Gevo to supply jet fuel to Virgin Australia\" data-tweet=\"$GEVO - Gevo to supply jet fuel to Virgin Australia https://seekingalpha.com/news/3299139-gevo-to-supply-jet-fuel-to-virgin-australia?source=tweet\" data-url=\"https://seekingalpha.com/news/3299139-gevo-to-supply-jet-fuel-to-virgin-australia\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:58 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3299138\" data-ts=\"1507060467\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FIT\" target=\"_blank\">FIT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3299138-oppenheimer-fitbit-looks-to-meet-low-ionic-expectations\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Oppenheimer: Fitbit looks to meet low Ionic expectations</a></h4><ul>   <li>Sell-through looks to be down 20-30% Y/Y at Fitbit (<a href=\"http://seekingalpha.com/symbol/FIT\" target=\"_blank\">FIT</a> <font color='red'>-3.6%</font>), Cleveland Research says, and channel inventory seems to be improving.</li>    <li>Shares have run hot over the past month, <font color='green'>up 13%</font>.</li>    <li>Channel fill for the Ionic watch appears to be ahead of initial supply, the firm says.</li>    <li>Meanwhile, Oppenheimer's Andrew Uerkwitz is staying bullish, saying a simple, fitness-first focus for Ionic along with more accessories <a href=\"http://www.marketwatch.com/story/fitbits-stock-falls-but-analyst-stays-bullish-on-upbeat-outlook-for-ionic-smartwatch-2017-10-03\" target=\"_blank\">positions it for audience expansion</a>.</li>    <li>\"With expectations low, [Fitbit] doesn't need a mega hit,\" Uerkwitz writes. \"It just needs to show it understands what is needed for the coming digital health era: an easy-to-use device that provides robust data, coaching and a long battery life.\"</li> </ul><div class=\"tiny-share-widget\" data-id=\"3299138\" data-linked=\"Oppenheimer: Fitbit looks to meet low Ionic expectations\" data-tweet=\"$FIT - Oppenheimer: Fitbit looks to meet low Ionic expectations https://seekingalpha.com/news/3299138-oppenheimer-fitbit-looks-to-meet-low-ionic-expectations?source=tweet\" data-url=\"https://seekingalpha.com/news/3299138-oppenheimer-fitbit-looks-to-meet-low-ionic-expectations\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:54 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>27&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3299137\" data-ts=\"1507060376\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SQ\" target=\"_blank\">SQ</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3299137-squares-big-run-continues\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Square&#39;s big run continues</a></h4><ul><li>The company today announced contactless debit card payments <a href=\"https://squareup.com/ca\" target=\"_blank\">are available</a> in Canada, and it will be waiving all debit card fees there for the rest of the year.</li><li>KeyBanc bull Josh Beck boosts his price target to $32 from $29, taking note of Square's (NYSE:<a href='https://seekingalpha.com/symbol/SQ' title='Square, Inc.'>SQ</a>) stickiness with large sellers. A KeyBanc survey shows 60% of large sellers being offered a better price elsewhere, but 80% planned to stick with Square.</li><li>Shares today are<font color='green'> higher by 2%</font>&nbsp;to $29.96, and now up 120% YTD.</li></ul><div class=\"tiny-share-widget\" data-id=\"3299137\" data-linked=\"Square&#39;s big run continues\" data-tweet=\"$SQ - Square&#39;s big run continues https://seekingalpha.com/news/3299137-squares-big-run-continues?source=tweet\" data-url=\"https://seekingalpha.com/news/3299137-squares-big-run-continues\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:52 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>46&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3299134\" data-ts=\"1507059710\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HMY\" target=\"_blank\">HMY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3299134-harmony-golds-kusasalethu-mine-resumes-full-operations\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Harmony Gold&#39;s Kusasalethu mine resumes full operations</a></h4><ul>     <li>Harmony Gold (<a href='https://seekingalpha.com/symbol/HMY' title='Harmony Gold Mining Company Limited'>HMY</a> <font color='green'>+3.1%</font>) says its Kusasalethu mine South Africa has <a href=\"http://www.miningweekly.com/article/harmony-golds-kusasalethu-mine-back-in-full-production-2017-10-03\" target=\"_blank\">resumed full production</a> after the facility was closed in August as government was investigating the cause of a seismic event that killed five workers.</li>     <li>Kusasalethu produces 15-20 kg/day of gold at full production, but HMY is not yet ready to offer revised guidance; HMY&rsquo;s FQ1 operating results will be published in late October or early November.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3299134\" data-linked=\"Harmony Gold&#39;s Kusasalethu mine resumes full operations\" data-tweet=\"$HMY - Harmony Gold&#39;s Kusasalethu mine resumes full operations https://seekingalpha.com/news/3299134-harmony-golds-kusasalethu-mine-resumes-full-operations?source=tweet\" data-url=\"https://seekingalpha.com/news/3299134-harmony-golds-kusasalethu-mine-resumes-full-operations\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:41 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3299128\" data-ts=\"1507059156\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/XBIO\" target=\"_blank\">XBIO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3299128-xenetic-biosciences-up-87-news-scarce\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Xenetic Biosciences up 87% but news scarce</a></h4><ul><li>Ultra-thinly traded nano cap Xenetic Biosciences (<a href='https://seekingalpha.com/symbol/XBIO' title='Xenetic Biosciences, Inc.'>XBIO</a> <font color='green'>+86.5%</font>) is up on a healthy 47x surge in volume, albeit on turnover of only 352K shares.</li><li>No particular news accounts for the action. Yesterday, the company <a href=\"https://seekingalpha.com/pr/16956630-xenetic-biosciences-provides-update-annual-meeting-stockholders\" target=\"_blank\">announced</a> another annual meeting postponement, originally set for August 16, then October 5. Management intends to hold the meeting before year-end.</li><li>The company's lead candidate is <a href=\"http://www.xeneticbio.com/product-pipeline/xbio-101\" target=\"_blank\">XBIO-101</a>, a small molecule immunomodulator and interferon inducer. Preliminary studies showed it to increase progesterone receptor (PrR) expression in endometrial tissue which may potentially resensitize endometrial tumor tissue to progestin therapy. A Phase 2 study is ongoing.</li></ul><div class=\"tiny-share-widget\" data-id=\"3299128\" data-linked=\"Xenetic Biosciences up 87% but news scarce\" data-tweet=\"$XBIO - Xenetic Biosciences up 87% but news scarce https://seekingalpha.com/news/3299128-xenetic-biosciences-up-87-news-scarce?source=tweet\" data-url=\"https://seekingalpha.com/news/3299128-xenetic-biosciences-up-87-news-scarce\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:32 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3299129\" data-ts=\"1507058633\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PSX\" target=\"_blank\">PSX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3299129-phillips-66-jumps-goldman-upgrades-to-buy\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Phillips 66 jumps as Goldman upgrades to Buy</a></h4><ul>     <li>Phillips 66 (<a href='https://seekingalpha.com/symbol/PSX' title='Phillips 66'>PSX</a> <font color='green'>+1.7%</font>) is higher after Goldman Sachs <a href=\"http://thefly.com/thestreet/realmoney/index.php/PSXid2617542/PSX-Phillips--upgraded-to-Buy-at-Goldman-Sachs\" target=\"_blank\">upgrades shares to Buy</a> from Neutral with a $109 price target.</li>     <li>Goldman's Neil Mehta says he is positive on potential lower capex in 2018-20 due to the roll off of major spending projects and believes growth from the in-service of projects is underappreciated; Mehta also expects PSX to benefit from a constructive near-term outlook for distillates.</li>     <li>At the same time, the firm downgrades Marathon Petroleum (<a href='https://seekingalpha.com/symbol/MPC' title='Marathon Petroleum Corp.'>MPC</a> <font color='green'>+0.6%</font>) to Neutral from Buy with a $63 price target, citing valuation.</li></ul><div class=\"tiny-share-widget\" data-id=\"3299129\" data-linked=\"Phillips 66 jumps as Goldman upgrades to Buy\" data-tweet=\"$PSX $PSX $MPC - Phillips 66 jumps as Goldman upgrades to Buy https://seekingalpha.com/news/3299129-phillips-66-jumps-goldman-upgrades-to-buy?source=tweet\" data-url=\"https://seekingalpha.com/news/3299129-phillips-66-jumps-goldman-upgrades-to-buy\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:23 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3299121\" data-ts=\"1507056914\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3299121-technology-top-gainers-losers-of-2-55-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Technology - Top Gainers / Losers as of 2:55 pm</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/TISA' title='Top Image Systems, Ltd.'>TISA</a> <font color='green'>+25%</font>. <a href='https://seekingalpha.com/symbol/EGAN' title='eGain Communications Corp.'>EGAN</a> <font color='green'>+14%</font>. <a href='https://seekingalpha.com/symbol/OCC' title='Optical Cable Corporation'>OCC</a> <font color='green'>+14%</font>. <a href='https://seekingalpha.com/symbol/ITI' title='Iteris, Inc'>ITI</a> <font color='green'>+12%</font>. <a href='https://seekingalpha.com/symbol/MANH' title='Manhattan Associates, Inc.'>MANH</a> <font color='green'>+10%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/IZEA' title='IZEA Worldwide, Inc.'>IZEA</a> <font color='red'>-12%</font>. <a href='https://seekingalpha.com/symbol/BNFT' title='Benefitfocus, Inc.'>BNFT</a> <font color='red'>-10%</font>. <a href='https://seekingalpha.com/symbol/TEUM' title='Pareteum Corporation'>TEUM</a> <font color='red'>-8%</font>. <a href='https://seekingalpha.com/symbol/NVMI' title='Nova Measuring Instruments Ltd.'>NVMI</a> <font color='red'>-7%</font>. <a href='https://seekingalpha.com/symbol/OPNT' title='Opiant Pharmaceuticals, Inc.'>OPNT</a> <font color='red'>-7%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3299121\" data-linked=\"Technology - Top Gainers / Losers as of 2:55 pm\" data-tweet=\"$TISA $EGAN $OCC - Technology - Top Gainers / Losers as of 2:55 pm https://seekingalpha.com/news/3299121-technology-top-gainers-losers-of-2-55-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3299121-technology-top-gainers-losers-of-2-55-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:55 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3299120\" data-ts=\"1507056556\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CSRA\" target=\"_blank\">CSRA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3299120-csra-announces-24_5m-epa-contract\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">CSRA announces $24.5M EPA contract</a></h4><ul><li>        CSRA (NYSE:<a href='https://seekingalpha.com/symbol/CSRA' title='CSRA Inc.'>CSRA</a>)&nbsp;<a href=\"https://www.csra.com/media-room/press-release/epa-awards-potential-245-million-contract-csra/\" target=\"_blank\">announces</a> an up to $24.5M five-year contract with the U.S. Environmental Protection Agency.</li><li>               The Scientific and Technical Support contract pertains to helping the EPA&rsquo;s Office of Water Engineering and Analysis Division with tasks including study design, lab method development, quality assurance, and data management.&nbsp;</li><li>CSRA shares are&nbsp;<font color='red'>down 2.16%</font>&nbsp;following this morning's Vertical Research <a href=\"https://www.google.com/url?sa=t&amp;rct=j&amp;q=&amp;esrc=s&amp;source=newssearch&amp;cd=1&amp;cad=rja&amp;uact=8&amp;ved=0ahUKEwiN8Y_bjtXWAhVF4iYKHWiQDP0QqQIIJygAMAA&amp;url=https%3A%2F%2Fwww.streetinsider.com%2FAnalyst%2BComments%2FUPDATE%253A%2BVertical%2BResearch%2BPartners%2BDowngrades%2BCSRA%2B%2528CSRA%2529%2Bto%2BSell%253B%2BMargin%2BHeadwinds%2F13352740.html&amp;usg=AOvVaw2z572bpKKpASQTnyKVHkcp\" target=\"_blank\">downgrade</a> from Hold to Sell.&nbsp;&nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3299120\" data-linked=\"CSRA announces $24.5M EPA contract\" data-tweet=\"$CSRA - CSRA announces $24.5M EPA contract https://seekingalpha.com/news/3299120-csra-announces-24_5m-epa-contract?source=tweet\" data-url=\"https://seekingalpha.com/news/3299120-csra-announces-24_5m-epa-contract\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:49 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3299118\" data-ts=\"1507056333\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TWX\" target=\"_blank\">TWX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3299118-consolidated-offering-customers-hbo-now\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Consolidated offering customers HBO Now</a></h4><ul>   <li>HBO (<a href=\"http://seekingalpha.com/symbol/TWX\" target=\"_blank\">TWX</a> <font color='green'>+0.4%</font>) has reached a deal to offer its HBO Now stand-alone streaming offering to <a href=\"http://www.fiercecable.com/online-video/hbo-now-lands-at-consolidated-communications\" target=\"_blank\">customers of Consolidated Communications</a> (<a href=\"http://seekingalpha.com/symbol/CNSL\" target=\"_blank\">CNSL</a> <font color='green'>+2.9%</font>).</li>    <li>Consolidated offers high-speed Internet and video service to business and residential across 24 states (residential in 11 states) and reported just over 1M connections (473K data, 106K video) in its last annual report.</li>    <li>HBO Now was reported to have passed 2M total subscribers earlier this year.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3299118\" data-linked=\"Consolidated offering customers HBO Now\" data-tweet=\"$TWX $TWX $CNSL - Consolidated offering customers HBO Now https://seekingalpha.com/news/3299118-consolidated-offering-customers-hbo-now?source=tweet\" data-url=\"https://seekingalpha.com/news/3299118-consolidated-offering-customers-hbo-now\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:45 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3299117\" data-ts=\"1507055583\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AG\" target=\"_blank\">AG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3299117-four-workers-die-first-majestic-silver-mine-in-mexico\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Four workers die at First Majestic Silver mine in Mexico</a></h4><ul>     <li>First Majestic Silver (<a href='https://seekingalpha.com/symbol/AG' title='First Majestic Silver Corp.'>AG</a> <font color='red'>-1.6%</font>) says <a href=\"https://seekingalpha.com/pr/16958419-first-majestic-reports-accident-la-encantada\" target=\"_blank\">four miners died</a> from gas intoxication which had accumulated at its La Encantada Silver Mine in Mexico.</li>     <li>AG says the accident occurred as part of the construction of a ramp at the site, and there was no explosion.</li>     <li>The company expects to resume mining operations on Oct. 4 but will keep the accident area closed until the investigation by Mexican authorities is completed.</li></ul><div class=\"tiny-share-widget\" data-id=\"3299117\" data-linked=\"Four workers die at First Majestic Silver mine in Mexico\" data-tweet=\"$AG - Four workers die at First Majestic Silver mine in Mexico https://seekingalpha.com/news/3299117-four-workers-die-first-majestic-silver-mine-in-mexico?source=tweet\" data-url=\"https://seekingalpha.com/news/3299117-four-workers-die-first-majestic-silver-mine-in-mexico\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:33 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>18&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3299111\" data-ts=\"1507054469\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AVGO\" target=\"_blank\">AVGO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3299111-arris-still-committed-to-ruckus-buy-amid-broadcom-brocade-delay\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Arris still committed to Ruckus buy amid Broadcom/Brocade delay</a></h4><ul>   <li>With Broadcom (<a href=\"http://seekingalpha.com/symbol/AVGO\" target=\"_blank\">AVGO</a> <font color='red'>-0.7%</font>), Brocade (<a href=\"http://seekingalpha.com/symbol/BRCD\" target=\"_blank\">BRCD</a> <font color='green'>+1.4%</font>) and Extreme Networks (<a href=\"http://seekingalpha.com/symbol/EXTR\" target=\"_blank\">EXTR</a> <font color='green'>+4.1%</font>) all agreeing to keep their deals together despite delays to the Broadcom-Brocade merger at the Committee for Foreign Investment in the U.S., Arris (<a href=\"http://seekingalpha.com/symbol/ARRS\" target=\"_blank\">ARRS</a> <font color='red'>-0.2%</font>) says it's <a href=\"https://finance.yahoo.com/news/arris-statement-ruckus-acquisition-following-131200039.html\" target=\"_blank\">still committed to buying</a> the Ruckus Wireless and ICX Switch businesses from Broadcom.</li>    <li>That purchase is contingent on Broadcom successfully closing on a purchase of Brocade, but Arris \"remains committed to our acquisition and associated strategy\" despite Broadcom's refiling with CFIUS.</li>    <li>Broadcom and Brocade had expected to close their deal by October's end; the refiling means they now see closing by Nov. 30, subject to CFIUS clearance.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3299111\" data-linked=\"Arris still committed to Ruckus buy amid Broadcom/Brocade delay\" data-tweet=\"$AVGO $AVGO $BRCD - Arris still committed to Ruckus buy amid Broadcom/Brocade delay https://seekingalpha.com/news/3299111-arris-still-committed-to-ruckus-buy-amid-broadcom-brocade-delay?source=tweet\" data-url=\"https://seekingalpha.com/news/3299111-arris-still-committed-to-ruckus-buy-amid-broadcom-brocade-delay\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:14 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3299110\" data-ts=\"1507054296\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FMSA\" target=\"_blank\">FMSA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3299110-bloomberg-belgian-miner-sibelco-weighs-takeover-bid-for-fairmount-santrol\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Bloomberg: Belgian miner Sibelco weighs takeover bid for Fairmount Santrol</a></h4><ul>     <li>Fairmount Santrol (<a href='https://seekingalpha.com/symbol/FMSA' title='Fairmount Santrol, Inc.'>FMSA</a> <font color='green'>+4.8%</font>) surges as much as 12% following a Bloomberg report that Belgian miner SCR-Sibelco is <a href=\"https://www.bloomberg.com/news/articles/2017-10-03/miner-sibelco-is-said-to-weigh-acquisition-of-fairmount-santrol\" target=\"_blank\">considering acquiring</a> the company and recently made an approach to the frack sand miner.</li>     <li>Among options under consideration, Sibelco may seek to reverse list Unimin Corp. U.S. unit into FMSA, according to the report.</li>     <li>Sibelco, founded in 1872, initially supplied silica sand to Belgium&rsquo;s major glass producers.</li></ul><div class=\"tiny-share-widget\" data-id=\"3299110\" data-linked=\"Bloomberg: Belgian miner Sibelco weighs takeover bid for Fairmount Santrol\" data-tweet=\"$FMSA - Bloomberg: Belgian miner Sibelco weighs takeover bid for Fairmount Santrol https://seekingalpha.com/news/3299110-bloomberg-belgian-miner-sibelco-weighs-takeover-bid-for-fairmount-santrol?source=tweet\" data-url=\"https://seekingalpha.com/news/3299110-bloomberg-belgian-miner-sibelco-weighs-takeover-bid-for-fairmount-santrol\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:11 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3299107\" data-ts=\"1507053759\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3299107-energy-materials-top-gainers-losers-of-2-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Energy/Materials - Top Gainers / Losers as of 2:00 pm</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/TGB' title='Taseko Mines Limited'>TGB</a> <font color='green'>+10%</font>. <a href='https://seekingalpha.com/symbol/FTK' title='Flotek Industries, Inc.'>FTK</a> <font color='green'>+9%</font>. <a href='https://seekingalpha.com/symbol/SID' title='Companhia Siderurgica Nacional'>SID</a> <font color='green'>+7%</font>. <a href='https://seekingalpha.com/symbol/TANH' title='Tantech Holdings'>TANH</a> <font color='green'>+7%</font>. <a href='https://seekingalpha.com/symbol/FMSA' title='Fairmount Santrol, Inc.'>FMSA</a> <font color='green'>+6%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/CCJ' title='Cameco Corporation'>CCJ</a> <font color='red'>-8%</font>. <a href='https://seekingalpha.com/symbol/PZG' title='Paramount Gold Nevada Corp.'>PZG</a> <font color='red'>-6%</font>. <a href='https://seekingalpha.com/symbol/USAU' title='U.S. Gold Corp.'>USAU</a> <font color='red'>-6%</font>. <a href='https://seekingalpha.com/symbol/OMN' title='OMNOVA Solutions Inc.'>OMN</a> <font color='red'>-6%</font>. <a href='https://seekingalpha.com/symbol/SNES' title='SenesTech'>SNES</a> <font color='red'>-6%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3299107\" data-linked=\"Energy/Materials - Top Gainers / Losers as of 2:00 pm\" data-tweet=\"$TGB $FTK $SID - Energy/Materials - Top Gainers / Losers as of 2:00 pm https://seekingalpha.com/news/3299107-energy-materials-top-gainers-losers-of-2-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3299107-energy-materials-top-gainers-losers-of-2-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:02 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3299096\" data-ts=\"1507050601\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TOL\" target=\"_blank\">TOL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3299096-homebuilders-continue-big-run-after-lennar-results\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Homebuilders continue big run after Lennar results</a></h4><ul><li>Lennar's&nbsp;<font color='green'>3.5%</font>&nbsp;post-earnings-beat gain is leading the <a href='https://seekingalpha.com/symbol/ITB' title='iShares U.S. Home Construction ETF'>ITB</a>&nbsp;<font color='green'>up 0.5%</font>&nbsp;vs. the S&amp;P 500's&nbsp;<font color='green'>0.1% advance</font>.</li><li>For the year, ITB is&nbsp;<font color='green'>ahead 35%</font>, besting the S&amp;P 500's impressive run by more than 2000 basis points.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3299059-lennar-2-percent-earnings-beat\" target=\"_blank\">Lennar up 2% after earnings beat</a> (Oct. 3)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3298901-lennar-beats-0_05-beats-revenue\" target=\"_blank\">Lennar beats by $0.05, beats on revenue</a> (Oct. 3)</li><li>Individual names today: Toll Brothers (<a href='https://seekingalpha.com/symbol/TOL' title='Toll Brothers Inc.'>TOL</a> <font color='green'>+0.8%</font>), KB Home (<a href='https://seekingalpha.com/symbol/KBH' title='KB Home'>KBH</a> <font color='green'>+0.3%</font>), Pulte (<a href='https://seekingalpha.com/symbol/PHM' title='PulteGroup, Inc.'>PHM</a> <font color='green'>+0.4%</font>), D.R. Horton (<a href='https://seekingalpha.com/symbol/DHI' title='D. R. Horton Inc.'>DHI</a> <font color='green'>+0.7%</font>)</li></ul><div class=\"tiny-share-widget\" data-id=\"3299096\" data-linked=\"Homebuilders continue big run after Lennar results\" data-tweet=\"$TOL $ITB $TOL - Homebuilders continue big run after Lennar results https://seekingalpha.com/news/3299096-homebuilders-continue-big-run-after-lennar-results?source=tweet\" data-url=\"https://seekingalpha.com/news/3299096-homebuilders-continue-big-run-after-lennar-results\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:10 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3299095\" data-ts=\"1507050030\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3299095-financials-top-5-gainers-losers-of-1-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Financials - Top 5 Gainers / Losers as of 1:00 PM</a></h4><ul><li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/SGLB' title='Sigma Labs, Inc.'>SGLB</a> <font color='green'>+13%</font>. <a href='https://seekingalpha.com/symbol/CNFR' title='Conifer Holdings'>CNFR</a> <font color='green'>+10%</font>.<a href='https://seekingalpha.com/symbol/YRD' title='Yirendai LTD.'>YRD</a> <font color='green'>+7%</font>. <a href='https://seekingalpha.com/symbol/JP' title='Jupai Holdings'>JP</a> <font color='green'>+6%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/PN' title='Patriot National, Inc.'>PN</a> <font color='red'>-10%</font>. <a href='https://seekingalpha.com/symbol/TRC' title='Tejon Ranch Co.'>TRC</a> <font color='red'>-7%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3299095\" data-linked=\"Financials - Top 5 Gainers / Losers as of 1:00 PM\" data-tweet=\"$SGLB $CNFR $YRD - Financials - Top 5 Gainers / Losers as of 1:00 PM https://seekingalpha.com/news/3299095-financials-top-5-gainers-losers-of-1-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3299095-financials-top-5-gainers-losers-of-1-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:00 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3299081\" data-ts=\"1507049573\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MYOV\" target=\"_blank\">MYOV</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3299081-positive-data-from-takedas-late-stage-study-of-uterine-fibroid-med-relugolix-stokes-u-s\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Positive data from Takeda&#39;s late-stage study of uterine fibroid med relugolix stokes U.S. licensee Myovant Sciences, shares up 33% since last week</a></h4><ul><li>Thinly traded Myovant Sciences (<a href='https://seekingalpha.com/symbol/MYOV' title='Myovant Sciences'>MYOV</a> <font color='green'>+7.5%</font>) adds to its up move on a 33% spike in volume, albeit on modest turnover of 85K. Shares have rallied&nbsp;<font color='green'>33%</font>&nbsp;since last week.</li><li>The catalyst appears to be <a href=\"https://seekingalpha.com/pr/16957272-myovant-sciences-announces-positive-top-line-results-takedas-phase-3-study-evaluating\" target=\"_blank\">positive data</a> from a Japan-based Phase 3 clinical trial assessing Takeda Pharmaceutical's (TKPYY <font color='green'>+0.5%</font>) relugolix for the treatment of women with uterine fibroids. The results showed relugolix to be statistically non-inferior (no worse than) to leuprorelin, a gonadotrophin-releasing hormone analogue used to treat a range of sex-hormone-related disorders such as prostate cancer and endometriosis. Its acts by rapidly lowering estrogen and progesterone when administered daily.</li><li>Takeda is conducting a second Phase 3 in Japanese women experiencing uterine fibroid-related pain. Preliminary topline data from the 70-subject study should be released this quarter. It plans to use the late-stage data to support its marketing application there.</li><li>Myovant has exclusive rights to relugolix in the U.S. It plans to use Takeda's data, together with results from two U.S.-based Phase 3s, LIBERTY 1&amp;2, to support its FDA filing. The primary completion date for both trials is December 2018.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3290189-evercore-likes-myovant-sees-three-bagger-shares-17-percent\" target=\"_blank\">Evercore likes Myovant, sees a three-bagger; shares up 17%</a> (Aug. 17)</li></ul><div class=\"tiny-share-widget\" data-id=\"3299081\" data-linked=\"Positive data from Takeda&#39;s late-stage study of uterine fibroid med relugolix stokes U.S. licensee Myovant Sciences, shares up 33% since last week\" data-tweet=\"$MYOV $MYOV $TAK - Positive data from Takeda&#39;s late-stage study of uterine fibroid med relugolix stokes U.S. licensee Myovant Sciences, shares up 33% since last week https://seekingalpha.com/news/3299081-positive-data-from-takedas-late-stage-study-of-uterine-fibroid-med-relugolix-stokes-u-s?source=tweet\" data-url=\"https://seekingalpha.com/news/3299081-positive-data-from-takedas-late-stage-study-of-uterine-fibroid-med-relugolix-stokes-u-s\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:52 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3299088\" data-ts=\"1507049115\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3299088-midday-gainers-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Midday Gainers / Losers</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/CLSN' title='Celsion Corporation'>CLSN</a> <font color='green'>+154%</font>. <a href='https://seekingalpha.com/symbol/ECYT' title='Endocyte, Inc.'>ECYT</a> <font color='green'>+63%</font>. <a href='https://seekingalpha.com/symbol/KOOL' title='Cesca Therapeutics Inc'>KOOL</a> <font color='green'>+33%</font>. <a href='https://seekingalpha.com/symbol/PHMD' title='PhotoMedex, Inc.'>PHMD</a> <font color='green'>+33%</font>. <a href='https://seekingalpha.com/symbol/NVIV' title='InVivo Therapeutics Holdings Corp'>NVIV</a> <font color='green'>+25%</font>. <a href='https://seekingalpha.com/symbol/SGBX' title='SG Blocks'>SGBX</a> <font color='green'>+25%</font>. BIOP <font color='green'>+17%</font>. <a href='https://seekingalpha.com/symbol/VICL' title='Vical Incorporated'>VICL</a> <font color='green'>+16%</font>. <a href='https://seekingalpha.com/symbol/ANTH' title='Anthera Pharmaceuticals, Inc.'>OTC:ANTH</a> <font color='green'>+16%</font>. <a href='https://seekingalpha.com/symbol/MNKD' title='MannKind Corporation'>MNKD</a> <font color='green'>+15%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/TTS' title='Tile Shop Holdings, Inc.'>TTS</a> <font color='red'>-34%</font>. <a href='https://seekingalpha.com/symbol/RDHL' title='RedHill Biopharma Ltd.'>RDHL</a> <font color='red'>-13%</font>. <a href='https://seekingalpha.com/symbol/SRAX' title='Social Reality Inc.'>SRAX</a> <font color='red'>-11%</font>. <a href='https://seekingalpha.com/symbol/CAPR' title='Capricor Therapeutics, Inc.'>CAPR</a> <font color='red'>-11%</font>. <a href='https://seekingalpha.com/symbol/AEGN' title='Aegion Corporation'>AEGN</a> <font color='red'>-10%</font>. <a href='https://seekingalpha.com/symbol/PN' title='Patriot National, Inc.'>PN</a> <font color='red'>-9%</font>. <a href='https://seekingalpha.com/symbol/SCMP' title='Sucampo Pharmaceuticals, Inc.'>SCMP</a> <font color='red'>-9%</font>. <a href='https://seekingalpha.com/symbol/AMMA-OLD' title='Alliance MMA'>AMMA-OLD</a> <font color='red'>-9%</font>. <a href='https://seekingalpha.com/symbol/OPNT' title='Opiant Pharmaceuticals, Inc.'>OPNT</a> <font color='red'>-8%</font>. <a href='https://seekingalpha.com/symbol/AKTX' title='Akari Therapeutics Plc'>AKTX</a> <font color='red'>-8%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3299088\" data-linked=\"Midday Gainers / Losers\" data-tweet=\"$CLSN $ECYT $THMO - Midday Gainers / Losers https://seekingalpha.com/news/3299088-midday-gainers-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3299088-midday-gainers-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:45 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>17&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3299084\" data-ts=\"1507048459\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/EIHDF\" target=\"_blank\">EIHDF</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3299084-888-holdings-shareholder-to-sell-large-block\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">888 Holdings shareholder to sell large block</a></h4><ul>     <li>Sinitus Nominees plans to sell its entire stake in 888 Holdings (<a href='https://seekingalpha.com/symbol/EIHDF' title='888 Holdings plc.'>OTCPK:EIHDF</a>), according to Bloomberg.</li><li>The transaction will see 46.28M shares go on the market.</li>     <li>Sinitus Nominees Limited is the trustee of the O Shaked Shares Trust for the gambling company's founders.</li>     <li>Shares of 888 Holdings are up 19% YTD.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3299084\" data-linked=\"888 Holdings shareholder to sell large block\" data-tweet=\"$EIHDF - 888 Holdings shareholder to sell large block https://seekingalpha.com/news/3299084-888-holdings-shareholder-to-sell-large-block?source=tweet\" data-url=\"https://seekingalpha.com/news/3299084-888-holdings-shareholder-to-sell-large-block\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:34 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3299082\" data-ts=\"1507047947\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ASTE\" target=\"_blank\">ASTE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3299082-astec-industriesplus-4-baird-upgrades\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Astec Industries +4% as Baird upgrades</a></h4><ul>     <li>Astec Industries (<a href='https://seekingalpha.com/symbol/ASTE' title='Astec Industries, Inc.'>ASTE</a> <font color='green'>+3.9%</font>) is higher after Baird <a href=\"https://www.streetinsider.com/Analyst+Comments/Baird+Upgrades+Astec+Industries+%28ASTE%29+to+Outperform/13352039.html\" target=\"_blank\">upgrades</a> shares to Outperform from Neutral and raises its price target to $65 from $56, as its core business shows strong orders in spite of tepid highway construction spending.</li>     <li>Baird notes another setback in the wood pellet plant technology adding yet more noise and drowning out otherwise strong core underlying business trends, such as non-WPP orders rising 14% in 2016 and up 18% YTD with backlog up 27%; in the firm's view, WPP noise confused investors, driving excess optimism in 2016 and the opposite this year.</li>     <li>ASTE announced yesterday that it <a href=\"https://seekingalpha.com/pr/16955864-astec-industries-inc-announces-acquisition-rexcon-llc\" target=\"_blank\">acquired</a> Wisconsin-based concrete batch plant manufacturer RexCon for $26M.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3299082\" data-linked=\"Astec Industries +4% as Baird upgrades\" data-tweet=\"$ASTE - Astec Industries +4% as Baird upgrades https://seekingalpha.com/news/3299082-astec-industriesplus-4-baird-upgrades?source=tweet\" data-url=\"https://seekingalpha.com/news/3299082-astec-industriesplus-4-baird-upgrades\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:25 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3299075\" data-ts=\"1507046840\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AAOI\" target=\"_blank\">AAOI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3299075-applied-optominus-4_7-craig-hallum-trims-bullish-target\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Applied Opto -4.7% as Craig-Hallum trims bullish target</a></h4><ul>   <li>Applied Optoelectronics (NASDAQ:<a href='https://seekingalpha.com/symbol/AAOI' title='Applied Optoelectronics, Inc.'>AAOI</a>) is <font color='red'>off 4.7%</font> after Craig-Hallum drops its price target to $80 from $95.</li>    <li>That cuts upside expectations to 30% from today's price (24% upside from yesterday's close); the firm still believes in the stock as a Buy.</li>    <li>But the company will see a challenge as Amazon makes a \"hard shift\" away from 40G optical, where AAOI is Amazon's main supplier, writes analyst Richard Shannon.</li>    <li>Intel is making inroads into 100G optics as well, he notes, and that could hit revenue growth as soon as Q4.</li>    <li>Source: Bloomberg</li> </ul><div class=\"tiny-share-widget\" data-id=\"3299075\" data-linked=\"Applied Opto -4.7% as Craig-Hallum trims bullish target\" data-tweet=\"$AAOI - Applied Opto -4.7% as Craig-Hallum trims bullish target https://seekingalpha.com/news/3299075-applied-optominus-4_7-craig-hallum-trims-bullish-target?source=tweet\" data-url=\"https://seekingalpha.com/news/3299075-applied-optominus-4_7-craig-hallum-trims-bullish-target\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:07 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>111&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3299071\" data-ts=\"1507046479\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3299071-consumer-top-gainers-losers-of-12-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Consumer - Top Gainers / Losers as of 12:00 pm</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/UQM' title='UQM Technologies, Inc'>UQM</a> <font color='green'>+6%</font>. <a href='https://seekingalpha.com/symbol/WPRT' title='Westport Fuel Systems, Inc.'>WPRT</a> <font color='green'>+5%</font>. <a href='https://seekingalpha.com/symbol/CALM' title='Cal-Maine Foods, Inc.'>CALM</a> <font color='green'>+5%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/REV' title='Revlon, Inc.'>REV</a> <font color='red'>-7%</font>. <a href='https://seekingalpha.com/symbol/FIZZ' title='National Beverage Corp.'>FIZZ</a> <font color='red'>-5%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3299071\" data-linked=\"Consumer - Top Gainers / Losers as of 12:00 pm\" data-tweet=\"$UQM $WPRT $CALM - Consumer - Top Gainers / Losers as of 12:00 pm https://seekingalpha.com/news/3299071-consumer-top-gainers-losers-of-12-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3299071-consumer-top-gainers-losers-of-12-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:01 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3299066\" data-ts=\"1507045939\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PULM\" target=\"_blank\">PULM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3299066-pulmatrix-nabs-second-qidp-tag-for-pulmazole-shares-up-1\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Pulmatrix nabs second QIDP tag for Pulmazole; shares up 1%</a></h4><ul><li>The FDA has designated Pulmatrix's (<a href='https://seekingalpha.com/symbol/PULM' title='Pulmatrix, Inc.'>PULM</a> <font color='green'>+1.4%</font>) Pulmazole (PUR1900) a Qualified Infectious Disease Product &#40;QIDP&#41; for the treatment of fungal infections in the lungs, the second such designation for the product (the first was fungal infections in CF patients, also an Orphan Drug use).</li><li>The specific indication is the treatment of pulmonary Aspergillus infections in patients with allergic bronchopulmonary aspergillosis, which includes the 1.5% of asthma sufferers with the malady.</li><li>QIDP status provides for accelerated review by the FDA and an additional five-year period of market exclusivity for the indication, if approved.</li></ul><div class=\"tiny-share-widget\" data-id=\"3299066\" data-linked=\"Pulmatrix nabs second QIDP tag for Pulmazole; shares up 1%\" data-tweet=\"$PULM - Pulmatrix nabs second QIDP tag for Pulmazole; shares up 1% https://seekingalpha.com/news/3299066-pulmatrix-nabs-second-qidp-tag-for-pulmazole-shares-up-1?source=tweet\" data-url=\"https://seekingalpha.com/news/3299066-pulmatrix-nabs-second-qidp-tag-for-pulmazole-shares-up-1\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:52 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3299064\" data-ts=\"1507045569\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/KR\" target=\"_blank\">KR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3299064-kroger-perks-up-on-m-chatter\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Kroger perks up on M&amp;A chatter</a></h4><ul><li>Kroger (<a href='https://seekingalpha.com/symbol/KR' title='Kroger Co.'>KR</a> <font color='green'>+3.4%</font>) is higher after a rumor of interest by Ahold (<a href='https://seekingalpha.com/symbol/AHODF' title='Koninklijke Ahold Delhaize N.V.'>OTCQX:AHODF</a>)&nbsp;in a takeover circulates.</li><li>Shares of Kroger slipped to a multi-year low of $19.69 earlier this week.</li></ul><div class=\"tiny-share-widget\" data-id=\"3299064\" data-linked=\"Kroger perks up on M&amp;A chatter\" data-tweet=\"$KR $KR $AHODF - Kroger perks up on M&amp;A chatter https://seekingalpha.com/news/3299064-kroger-perks-up-on-m-chatter?source=tweet\" data-url=\"https://seekingalpha.com/news/3299064-kroger-perks-up-on-m-chatter\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:46 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>84&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3299063\" data-ts=\"1507045541\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FNMA\" target=\"_blank\">FNMA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3299063-fhfas-watt-calls-for-frannie-capital-buffer\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FHFA&#39;s Watt calls for Frannie capital buffer</a></h4><ul><li>FHFA Director Mel Watt <a href=\"https://www.fhfa.gov/Media/PublicAffairs/Pages/Statement-of-Melvin-L--Watt,-Director,-FHFA,-Before-the-U-S--House-of-Representatives-Committee-on-Financial-Services.aspx\" target=\"_blank\">says it would be</a> \"irresponsible\" for the GSEs not to have a substantial capital buffer to weather operating losses without having to draw additional taxpayer support.</li><li>The buffers are set to be cut to zero on Jan. 1.</li><li>He makes clear that any steps the FHFA may take to avoid said draws shouldn't be read as the agency trying to influence the debate on housing finance reform.</li><li>Fannie (<a href='https://seekingalpha.com/symbol/FNMA' title='Fannie Mae'>OTCQB:FNMA</a>) and Freddie (<a href='https://seekingalpha.com/symbol/FMCC' title='Freddie Mac'>OTCQB:FMCC</a>) earlier had sizable gains perhaps on the idea Watt was going to let them retain some earnings, but both have returned to about flat on the session.</li></ul><div class=\"tiny-share-widget\" data-id=\"3299063\" data-linked=\"FHFA&#39;s Watt calls for Frannie capital buffer\" data-tweet=\"$FNMA $FNMA $FMCC - FHFA&#39;s Watt calls for Frannie capital buffer https://seekingalpha.com/news/3299063-fhfas-watt-calls-for-frannie-capital-buffer?source=tweet\" data-url=\"https://seekingalpha.com/news/3299063-fhfas-watt-calls-for-frannie-capital-buffer\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:45 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>56&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3299059\" data-ts=\"1507045062\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LEN\" target=\"_blank\">LEN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3299059-lennar-up-2-after-earnings-beat\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Lennar up 2% after earnings beat</a></h4><ul><li>FQ3 net earnings of $249.2M or $1.06 per share vs. $235.8M and $1.01 a year ago and $1.01 expected.</li><li>Deliveries up 12% to 7,598 homes.</li><li>New orders up 8% to 7,610 homes; up 14% in dollar value to $2.9B.</li><li>Backlogs up 10% in homes, up 18% in dollar value.</li><li>Gross margin on home sales of 2.8% up 20 basis points.</li><li>Sales incentives per home delivery of 5.5% were the lowest since 2006.</li><li>This season's hurricanes should push about 950 closings from this year to 2018.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3298901-lennar-beats-0_05-beats-revenue\" target=\"_blank\">Lennar beats by $0.05, beats on revenue</a> (Oct. 3)</li><li><a href='https://seekingalpha.com/symbol/LEN' title='Lennar Corporation'>LEN</a>&nbsp;<font color='green'>+2.35%</font></li></ul><div class=\"tiny-share-widget\" data-id=\"3299059\" data-linked=\"Lennar up 2% after earnings beat\" data-tweet=\"$LEN - Lennar up 2% after earnings beat https://seekingalpha.com/news/3299059-lennar-up-2-after-earnings-beat?source=tweet\" data-url=\"https://seekingalpha.com/news/3299059-lennar-up-2-after-earnings-beat\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:37 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3299058\" data-ts=\"1507044989\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FFIV\" target=\"_blank\">FFIV</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3299058-f5-networks-slides-deutsche-bank-trims-targets\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">F5 Networks slides as Deutsche Bank trims targets</a></h4><ul>   <li>F5 Networks (NASDAQ:<a href='https://seekingalpha.com/symbol/FFIV' title='F5 Networks, Inc.'>FFIV</a>) is on the skids, <font color='red'>down 3.8%</font>, with Deutsche Bank trimming its price target and reiterating a Sell amid hot cloud competition.</li>    <li>The firm lowered its target to $90 from $100, implying 24% further downside from today's lower price, with Amazon Web Services a particular rival threatening its position in hyperscale clouds.</li>    <li>Applying \"fundamental caution,\" analyst Vijay Bhagavath has trimmed expected Q4 revenues to $525.8M from $531.4M (and vs. consensus for $534.8M), with declines expected across software and subscriptions, and cut expected EPS to $2.12 from $2.16 (and further below Street expectations for $2.20).</li>    <li>Source: Bloomberg</li> </ul><div class=\"tiny-share-widget\" data-id=\"3299058\" data-linked=\"F5 Networks slides as Deutsche Bank trims targets\" data-tweet=\"$FFIV - F5 Networks slides as Deutsche Bank trims targets https://seekingalpha.com/news/3299058-f5-networks-slides-deutsche-bank-trims-targets?source=tweet\" data-url=\"https://seekingalpha.com/news/3299058-f5-networks-slides-deutsche-bank-trims-targets\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:36 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3299055\" data-ts=\"1507044752\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PGHEF\" target=\"_blank\">PGHEF</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3299055-financial-post-billionaire-schulich-goes-all-in-on-pengrowth-energy\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Financial Post: Billionaire Schulich goes &quot;all in&quot; on Pengrowth Energy</a></h4><ul>     <li>Billionaire investor Seymour Schulich <a href=\"http://business.financialpost.com/commodities/energy/billionaire-seymour-schullich-goes-all-in-on-pengrowth-energy-sending-shares-soaring\" target=\"_blank\">bought millions of additional shares</a> in Pengrowth Energy (PGH <font color='green'>+5.2%</font>) in recent weeks, sending the stock soaring and forcing the company <a href=\"https://seekingalpha.com/pr/16950064-pengrowth-comments-trading-activity\" target=\"_blank\">last week</a> to publicly say it did not know why the shares were moving so quickly.</li><li>Shulich tells <em>Financial Post</em> that he had gone \"all in\" on the company - increasing his stake to 130M shares at the end of last week, or 24% of the shares, from owning 19% in July - because he believes \"oil and gas are going up.\"</li><li>After trending downward for six months, PGH more than doubled in the course of two  weeks during Sept. 15-26, a period during which Schulich says he was buying shares in large  volumes.</li><li>Schulich says he is not concerned about PGH&rsquo;s debt levels and  expects the company to eventually strike deals to lower its overall debt while oil and gas prices rise; he is also bullish on  PGH's Lindbergh steam-based oil sands project, which  he says has low operating costs, and its position in the prolific  Montney natural gas play.</li></ul><div class=\"tiny-share-widget\" data-id=\"3299055\" data-linked=\"Financial Post: Billionaire Schulich goes &quot;all in&quot; on Pengrowth Energy\" data-tweet=\"$PGHEF - Financial Post: Billionaire Schulich goes &quot;all in&quot; on Pengrowth Energy https://seekingalpha.com/news/3299055-financial-post-billionaire-schulich-goes-all-in-on-pengrowth-energy?source=tweet\" data-url=\"https://seekingalpha.com/news/3299055-financial-post-billionaire-schulich-goes-all-in-on-pengrowth-energy\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:32 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>34&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3299046\" data-ts=\"1507043939\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RIGL\" target=\"_blank\">RIGL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3299046-rigels-fostamatinib-successful-in-first-stage-of-mid-stage-study-in-rare-type-of-anemia\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Rigel&#39;s fostamatinib successful in first stage of mid-stage study in rare type of anemia; shares down 6% on profit-taking</a></h4><ul><li>Rigel Pharmaceuticals (<a href='https://seekingalpha.com/symbol/RIGL' title='Rigel Pharmaceuticals, Inc.'>RIGL</a> <font color='red'>-6.1%</font>) <a href=\"https://seekingalpha.com/pr/16957506-fostamatinib-meets-pre-specified-primary-endpoint-stage-1-autoimmune-hemolytic-anemia-aiha\" target=\"_blank\">announces</a> positive results from Stage 1 of its open-label, two-stage Phase 2 clinical trial, <a href=\"https://clinicaltrials.gov/ct2/show/NCT02612558?term=fostamatinib&amp;draw=1&amp;rank=12\" target=\"_blank\">SOAR</a>, assessing Tavalisse (fostamatinib) in patients with warm antibody <a href=\"https://www.healthline.com/health/idiopathic-autoimmune-hemolytic-anemia#overview1\" target=\"_blank\">autoimmune hemolytic anemia</a> &#40;AIHA&#41;, a rare blood disorder in which the body destroys red blood cells faster than it produces them.</li><li>On a preliminary basis, the study achieved its Stage 1 primary efficacy endpoint. Responders were defined as those achieving a hemoglobin level greater than 10 g/dL and at least a 2 g/dL increase from baseline. 17 patients are enrolled. Four responded during the 12-week evaluation period and two more met the response criteria in the extension study after 12 weeks of treatment, implying a response rate of 35.3%. Two subjects withdrew due to non-safety issues.</li><li>The safety profile of fostamatinib was consistent with existing data. Two deaths occurred in the study due to non-treatment-related serious adverse events (skin necrosis and infection, pneumonia). A third participant experienced a non-treatment-related serious adverse event, but recovered and continued treatment.</li><li>Enrollment in the 20-subject Stage 2 portion will now commence.</li><li>Compete data will be submitted for presentation as a future medical conference.</li><li>Shares are down on profit taking from yesterday's&nbsp;<font color='green'>~33%</font>&nbsp;up move stoked by the news that there will be no Ad Com review for fostamatinib for the treatment of immune thrombocytopenia.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3298670-ad-com-review-rigels-marketing-application-thrombocytopenia-med-fostamatinib-shares-ahead-14\" target=\"_blank\">No Ad Com review for Rigel's marketing application for thrombocytopenia med fostamatinib; shares ahead 14% premarket</a> (Oct. 2)</li></ul><div class=\"tiny-share-widget\" data-id=\"3299046\" data-linked=\"Rigel&#39;s fostamatinib successful in first stage of mid-stage study in rare type of anemia; shares down 6% on profit-taking\" data-tweet=\"$RIGL - Rigel&#39;s fostamatinib successful in first stage of mid-stage study in rare type of anemia; shares down 6% on profit-taking https://seekingalpha.com/news/3299046-rigels-fostamatinib-successful-in-first-stage-of-mid-stage-study-in-rare-type-of-anemia?source=tweet\" data-url=\"https://seekingalpha.com/news/3299046-rigels-fostamatinib-successful-in-first-stage-of-mid-stage-study-in-rare-type-of-anemia\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:18 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3299008\" data-ts=\"1507042898\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3299008-healthcare-top-5-gainers-losers-of-11-00\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Healthcare - Top 5 Gainers / Losers as of 11:00 am</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/CLSN' title='Celsion Corporation'>CLSN</a> <font color='green'>+123%</font>. <a href='https://seekingalpha.com/symbol/ECYT' title='Endocyte, Inc.'>ECYT</a> <font color='green'>+61%</font>. <a href='https://seekingalpha.com/symbol/KOOL' title='Cesca Therapeutics Inc'>KOOL</a> <font color='green'>+47%</font>. <a href='https://seekingalpha.com/symbol/VICL' title='Vical Incorporated'>VICL</a> <font color='green'>+21%</font>. ETRM <font color='green'>+14%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/VERU' title='Veru Inc.'>VERU</a> <font color='red'>-11%</font>. <a href='https://seekingalpha.com/symbol/RDHL' title='RedHill Biopharma Ltd.'>RDHL</a> <font color='red'>-11%</font>. <a href='https://seekingalpha.com/symbol/RIGL' title='Rigel Pharmaceuticals, Inc.'>RIGL</a> <font color='red'>-9%</font>. <a href='https://seekingalpha.com/symbol/ARDM' title='Aradigm Corp.'>OTC:ARDM</a> <font color='red'>-8%</font>. <a href='https://seekingalpha.com/symbol/SCMP' title='Sucampo Pharmaceuticals, Inc.'>SCMP</a> <font color='red'>-7%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3299008\" data-linked=\"Healthcare - Top 5 Gainers / Losers as of 11:00 am\" data-tweet=\"$CLSN $ECYT $THMO - Healthcare - Top 5 Gainers / Losers as of 11:00 am https://seekingalpha.com/news/3299008-healthcare-top-5-gainers-losers-of-11-00?source=tweet\" data-url=\"https://seekingalpha.com/news/3299008-healthcare-top-5-gainers-losers-of-11-00\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:01 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3299040\" data-ts=\"1507042746\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LOGM\" target=\"_blank\">LOGM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3299040-baird-upgrades-logmein\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Baird upgrades LogMeIn</a></h4><ul><li>           Baird <a href=\"https://www.benzinga.com/analyst-ratings/upgrades/17/10/10131821/benzingas-top-upgrades-downgrades-for-october-3-2017\" target=\"_blank\">upgrades</a> LogMeIn (NASDAQ:<a href='https://seekingalpha.com/symbol/LOGM' title='LogMeIn, Inc.'>LOGM</a>) from Neutral to Outperform. </li><li>           Latest analyst standings: 2 Buy, 6 Outperform, and 2 Hold. &nbsp; </li><li>           Median price target: $134.50. </li><li> LogMeIn shares are&nbsp;<font color='green'>up 2.25%</font>.&nbsp; </li></ul><div class=\"tiny-share-widget\" data-id=\"3299040\" data-linked=\"Baird upgrades LogMeIn\" data-tweet=\"$LOGM - Baird upgrades LogMeIn https://seekingalpha.com/news/3299040-baird-upgrades-logmein?source=tweet\" data-url=\"https://seekingalpha.com/news/3299040-baird-upgrades-logmein\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:59 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3299039\" data-ts=\"1507042704\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DAL\" target=\"_blank\">DAL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3299039-airline-stocks-jet-higher\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Airline stocks jet higher</a></h4><ul><li>There's some strong moves in the airline sector after Delta Air Lines (<a href='https://seekingalpha.com/symbol/DAL' title='Delta Air Lines, Inc.'>DAL</a> <font color='green'>+4.7%</font>) updated guidance earlier today. Though Delta clipped its operating margin view due to the impact of Hurricane Irma, it appears that the damage was less than anticipated.</li><li>Gainers include JetBlue (<a href='https://seekingalpha.com/symbol/JBLU' title='JetBlue Airways Corporation'>JBLU</a> <font color='green'>+5.2%</font>), American Airlines Group (<a href='https://seekingalpha.com/symbol/AAL' title='American Airlines Group'>AAL</a> <font color='green'>+3.8%</font>), Alaska Air Group (<a href='https://seekingalpha.com/symbol/ALK' title='Alaska Air Group, Inc.'>ALK</a> <font color='green'>+3.4%</font>), Hawaiian Holdings (<a href='https://seekingalpha.com/symbol/HA' title='Hawaiian Holdings, Inc.'>HA</a> <font color='green'>+3%</font>), Spirit Airlines (<a href='https://seekingalpha.com/symbol/SAVE' title='Spirit Airlines'>SAVE</a> <font color='green'>+4.5%</font>), United Continental (<a href='https://seekingalpha.com/symbol/UAL' title='United Continental Holdings, Inc'>UAL</a> <font color='green'>+3.8%</font>), SkyWest (<a href='https://seekingalpha.com/symbol/SKYW' title='SkyWest, Inc.'>SKYW</a> <font color='green'>+4%</font>), Southwest Airlines (<a href='https://seekingalpha.com/symbol/LUV' title='Southwest Airlines Co.'>LUV</a> <font color='green'>+2.8%</font>) and Allegiant Travel (<a href='https://seekingalpha.com/symbol/ALGT' title='Allegiant Travel Company'>ALGT</a> <font color='green'>+2.1%</font>).</li><li>Previously: <a href=\"https://seekingalpha.com/news/3298974-delta-air-lines-updates-traffic-hurricane-impact\" target=\"_blank\">Delta Air Lines updates on traffic, hurricane impact</a> (Oct. 3)</li></ul><div class=\"tiny-share-widget\" data-id=\"3299039\" data-linked=\"Airline stocks jet higher\" data-tweet=\"$DAL $DAL $JBLU - Airline stocks jet higher https://seekingalpha.com/news/3299039-airline-stocks-jet-higher?source=tweet\" data-url=\"https://seekingalpha.com/news/3299039-airline-stocks-jet-higher\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:58 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>24&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3299036\" data-ts=\"1507042338\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MANH\" target=\"_blank\">MANH</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3299036-suntrust-upgrades-manhattan-associates\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">SunTrust upgrades Manhattan Associates</a></h4><ul><li>SunTrust Robinson Humphrey <a href=\"https://www.benzinga.com/analyst-ratings/upgrades/17/10/10131821/benzingas-top-upgrades-downgrades-for-october-3-2017\" target=\"_blank\">upgrades</a> Manhattan Associates (NASDAQ:<a href='https://seekingalpha.com/symbol/MANH' title='Manhattan Associates, Inc.'>MANH</a>) from Hold to Buy following yesterday&rsquo;s grocery deal.</li><li>Manhattan Associates shares are&nbsp;up 13.54%</li><li>Previously: <a href=\"https://seekingalpha.com/news/3298807-manhattan-associates-supermarket-deal\" target=\"_blank\">Manhattan Associates up on supermarket deal</a> (Oct. 2)</li><li>Update with analyst comments:</li><li>SunTrust analyst Terry Tillman says the risk-reward balance is favorable at the current price and thinks software buying behavior can remain strong even with Amazon competition.</li><li>Tillman increases Manhattan Associates' price target from $44 to $55.</li><li>Source: Bloomberg First Word</li></ul><div class=\"tiny-share-widget\" data-id=\"3299036\" data-linked=\"SunTrust upgrades Manhattan Associates\" data-tweet=\"$MANH - SunTrust upgrades Manhattan Associates https://seekingalpha.com/news/3299036-suntrust-upgrades-manhattan-associates?source=tweet\" data-url=\"https://seekingalpha.com/news/3299036-suntrust-upgrades-manhattan-associates\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:52 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3299033\" data-ts=\"1507042149\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/URBN\" target=\"_blank\">URBN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3299033-urban-outfitters-falls-after-deutsche-bank-warns-on-valuation\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Urban Outfitters falls after Deutsche Bank warns on valuation</a></h4><ul><li>Urban Outfitters (<a href='https://seekingalpha.com/symbol/URBN' title='Urban Outfitters, Inc.'>URBN</a> <font color='red'>-5.2%</font>) trades lower after Deutsche Bank <a href=\"http://www.barrons.com/articles/urban-outfitters-the-higher-they-go-the-farther-they-fall-1507039354\" target=\"_blank\">downgrades</a> the retailer to Sell from Hold.</li><li>The firm warns on margin pressure for the Urban Outfitters brand and thinks valuation is a reach after the +40% rally in shares since early August.</li><li>DB sets a price target of $19 on URBN.</li></ul><div class=\"tiny-share-widget\" data-id=\"3299033\" data-linked=\"Urban Outfitters falls after Deutsche Bank warns on valuation\" data-tweet=\"$URBN - Urban Outfitters falls after Deutsche Bank warns on valuation https://seekingalpha.com/news/3299033-urban-outfitters-falls-after-deutsche-bank-warns-on-valuation?source=tweet\" data-url=\"https://seekingalpha.com/news/3299033-urban-outfitters-falls-after-deutsche-bank-warns-on-valuation\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:49 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3299031\" data-ts=\"1507042082\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CCJ\" target=\"_blank\">CCJ</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3299031-camecominus-6-after-scotia-downgrades-on-weak-uranium-outlook\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Cameco -6% after Scotia downgrades on weak uranium outlook</a></h4><ul>     <li>Cameco (<a href='https://seekingalpha.com/symbol/CCJ' title='Cameco Corporation'>CCJ</a> <font color='red'>-6%</font>) falls as much as 7% to its lowest in nearly a year after Scotia Capital <a href=\"https://www.streetinsider.com/Downgrades/Scotiabank+Downgrades+Cameco+Corporation+%28CCJ%29+to+Sector+Underperform/13351261.html\" target=\"_blank\">downgrades</a> shares to Sector Underperform from Sector Perform with a C$10 price target, cut from $C14.50, citing a \"materially weaker fundamental outlook for uranium.\"</li>     <li>Scotia expects the uranium market to remain in structural surplus until early in the next decade and cuts its U308 price estimates by an average of 27% for 2018-22; the firm also believes it would be prudent for CCJ to reduce its dividend.</li><li>ETFs:&nbsp;<a href='https://seekingalpha.com/symbol/URA' title='Global X Uranium ETF'>URA</a>, <a href='https://seekingalpha.com/symbol/NLR' title='VanEck Vectors Uranium+Nuclear Energy ETF'>NLR</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3299031\" data-linked=\"Cameco -6% after Scotia downgrades on weak uranium outlook\" data-tweet=\"$CCJ $CCJ $URA - Cameco -6% after Scotia downgrades on weak uranium outlook https://seekingalpha.com/news/3299031-camecominus-6-after-scotia-downgrades-on-weak-uranium-outlook?source=tweet\" data-url=\"https://seekingalpha.com/news/3299031-camecominus-6-after-scotia-downgrades-on-weak-uranium-outlook\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:48 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>234&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3299027\" data-ts=\"1507042047\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CLSN\" target=\"_blank\">CLSN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3299027-celsions-dna-immunotherapy-candidate-genminus-1-shows-continued-positive-effect-in-early\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Celsion&#39;s DNA immunotherapy candidate GEN-1 shows continued positive effect in early-stage ovarian cancer study; shares ahead 130%</a></h4><ul><li>Thinly traded nano cap Celsion (<a href='https://seekingalpha.com/symbol/CLSN' title='Celsion Corporation'>CLSN</a> <font color='green'>+129.8%</font>) is up on a whopping 36x surge in volume in response to its <a href=\"https://seekingalpha.com/pr/16958018-celsion-announces-final-clinical-translational-research-data-ovation-study-aacr-special\" target=\"_blank\">announcement </a>of final results from a <a href=\"https://clinicaltrials.gov/ct2/show/NCT02480374?term=celsion&amp;draw=1&amp;rank=9\" target=\"_blank\">Phase 1b dose-escalating study</a> of DNA immunotherapy GEN-1 in patients with advanced Stage III/IV ovarian cancer. The data were presented yesterday evening at the American Association of Cancer Research Special Conference in Pittsburgh, PA.</li><li>Of the 14 patients who completed the study, two were complete responders, 10 were partial responders and two had stable disease, implying a 100% disease control rate and an 86% objective response rate.</li><li><a href=\"http://celsion.com/gen-1/\" target=\"_blank\">GEN-1</a> is an interleukin 12 (IL-12) DNA plasmid vector encased in a nanoparticle delivery system, a technology platform the company calls <a href=\"http://celsion.com/theraplas/\" target=\"_blank\">TheraPlas</a>. It is designed to stimulate the local production and secretion of IL-12, a potent inducer of anti-cancer immunity, around the tumor site.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3276974-celsion-completes-ovation-study-provides-update-advanced-stage-iii-iv-ovarian-cancer-shares\" target=\"_blank\">Celsion completes OVATION study and provides update on advanced stage III and IV Ovarian Cancer; shares ahead 34% premarket</a> (July 5)</li></ul><div class=\"tiny-share-widget\" data-id=\"3299027\" data-linked=\"Celsion&#39;s DNA immunotherapy candidate GEN-1 shows continued positive effect in early-stage ovarian cancer study; shares ahead 130%\" data-tweet=\"$CLSN - Celsion&#39;s DNA immunotherapy candidate GEN-1 shows continued positive effect in early-stage ovarian cancer study; shares ahead 130% https://seekingalpha.com/news/3299027-celsions-dna-immunotherapy-candidate-genminus-1-shows-continued-positive-effect-in-early?source=tweet\" data-url=\"https://seekingalpha.com/news/3299027-celsions-dna-immunotherapy-candidate-genminus-1-shows-continued-positive-effect-in-early\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:47 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>26&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3299019\" data-ts=\"1507040987\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TSLA\" target=\"_blank\">TSLA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3299019-investor-bets-pour-in-on-tesla-gm-and-ford\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Investor bets pour in on Tesla, GM and Ford</a></h4><ul> <li>Tesla (<a href='https://seekingalpha.com/symbol/TSLA' title='Tesla, Inc.'>TSLA</a> <font color='red'>-1.7%</font>) is lower after the pace of Model 3 production during September disappointed some investors.</li> <li>Investment firms are mainly reiterating their prior ratings on Tesla, although with more than a little flare. Cowen says the \"production hell\" it anticipated for the Model 3 is playing out, while Consumer Edge and Morgan Stanley have their eyes on the long game strategy of Tesla to deliver quality early and quantity later. Baird recommends buying into the weakness, <a href=\"http://www.marketwatch.com/story/tesla-upgrades-its-fy17-delivery-outlook-baird-analyst-advises-aggressive-buying-2017-10-03\" target=\"_blank\">reminding</a> that announcements on the Tesla truck product and Tesla Energy initiatives are future catalysts.</li> <li>The dip in Tesla coincides with a strong day for Ford (<a href='https://seekingalpha.com/symbol/F' title='Ford Motor Company'>F</a> <font color='green'>+2.1%</font>)&nbsp;and General Motors (<a href='https://seekingalpha.com/symbol/GM' title='General Motors Company'>GM</a> <font color='green'>+2.9%</font>), after both automakers torched sales estimates with their September sales reports (<a href=\"https://seekingalpha.com/news/3298984-truck-sales-dazzle-ford\" target=\"_blank\">Ford</a>, <a href=\"https://seekingalpha.com/news/3298991-gm-rallies-topping-u-s-sales-estimates\" target=\"_blank\">GM</a>). There is also an interesting dynamic in play as the Detroit automakers are starting to be seen more as bets on the evolution of EVs, mobility innovation and autonomous driving than they were in the past. Is it possible all three auto stocks see significant share price gains as Auto 2.0 plays out or is there not nearly enough profitability to go around?</li> </ul><div class=\"tiny-share-widget\" data-id=\"3299019\" data-linked=\"Investor bets pour in on Tesla, GM and Ford\" data-tweet=\"$TSLA $TSLA $F - Investor bets pour in on Tesla, GM and Ford https://seekingalpha.com/news/3299019-investor-bets-pour-in-on-tesla-gm-and-ford?source=tweet\" data-url=\"https://seekingalpha.com/news/3299019-investor-bets-pour-in-on-tesla-gm-and-ford\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:29 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>96&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3299015\" data-ts=\"1507040495\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AEGN\" target=\"_blank\">AEGN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3299015-aegion-updates-on-strategic-actions\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Aegion updates on strategic actions</a></h4><ul><li>Aegion (NASDAQ:<a href='https://seekingalpha.com/symbol/AEGN' title='Aegion Corporation'>AEGN</a>) shares are <font color='red'>down almost 12%</font> in early trade after the company provided an update to its previously announced restructuring plan and the related impact to its upcoming results.</li><li>\"It will be difficult to recover in Q4 from the impact of the recent hurricanes and the financial challenges experienced in Q3 in Denmark, Australia and Fyfe North America,\" <a href=\"https://seekingalpha.com/pr/16957199-aegion-corporation-provides-update-strategic-actions-third-quarter-activities\" target=\"_blank\">said</a> CEO Charles Gordon. \"We expect the results of our restructuring actions combined with the momentum in key markets will provide a solid foundation for Aegion to achieve much stronger results in 2018.\"</li></ul><div class=\"tiny-share-widget\" data-id=\"3299015\" data-linked=\"Aegion updates on strategic actions\" data-tweet=\"$AEGN - Aegion updates on strategic actions https://seekingalpha.com/news/3299015-aegion-updates-on-strategic-actions?source=tweet\" data-url=\"https://seekingalpha.com/news/3299015-aegion-updates-on-strategic-actions\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:21 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3299014\" data-ts=\"1507040356\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CPTA\" target=\"_blank\">CPTA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3299014-capitala-finance-tumbles-8-after-slashing-dividend\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Capitala Finance tumbles 8% after slashing dividend</a></h4><ul><li>Judging by the price action so far, <a href=\"https://seekingalpha.com/news/3298845-capitala-finance-declares-0_0833-dividend\" target=\"_blank\">the 36% chop</a> in the monthly dividend was larger than expected.</li><li>CEO Joseph Alala says the company is \"pursuing a more conservative strategy targeting more senior secured and unitranche loans with lower aggregate average yields instead of unsecured and mezzanine loans with higher aggregate yields but with higher associated risk.\"</li><li><a href='https://seekingalpha.com/symbol/CPTA' title='Capitala Finance Corp'>CPTA</a><font color='red'> -8%</font>&nbsp;to $9.15, and now&nbsp;<font color='red'>off 31%</font>&nbsp;over the past three months.</li></ul><div class=\"tiny-share-widget\" data-id=\"3299014\" data-linked=\"Capitala Finance tumbles 8% after slashing dividend\" data-tweet=\"$CPTA - Capitala Finance tumbles 8% after slashing dividend https://seekingalpha.com/news/3299014-capitala-finance-tumbles-8-after-slashing-dividend?source=tweet\" data-url=\"https://seekingalpha.com/news/3299014-capitala-finance-tumbles-8-after-slashing-dividend\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:19 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>15&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3299004\" data-ts=\"1507039385\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CRMT\" target=\"_blank\">CRMT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3299004-automobile-sector-jolted-strong-u-s-sales-reports\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Automobile sector jolted by strong U.S. sales reports</a></h4><ul> <li>A string of U.S. sales reports from automobile manufacturers ahead of analyst expectations has sparked the broad auto sector.</li> <li>Auto retailers America's Car-Mart (<a href='https://seekingalpha.com/symbol/CRMT' title='America&#39;s Car-Mart, Inc.'>CRMT</a> <font color='green'>+2.7%</font>), AutoNation (<a href='https://seekingalpha.com/symbol/AN' title='AutoNation Inc'>AN</a> <font color='green'>+1.6%</font>), Group 1 Automotive (<a href='https://seekingalpha.com/symbol/GPI' title='Group 1 Automotive Inc.'>GPI</a> <font color='green'>+1.7%</font>), Penske Automotive Group (<a href='https://seekingalpha.com/symbol/PAG' title='Penske Automotive Group, Inc.'>PAG</a> <font color='green'>+1.8%</font>), Lithia Motors (<a href='https://seekingalpha.com/symbol/LAD' title='Lithia Motors, Inc.'>LAD</a> <font color='green'>+0.7%</font>), Sonic Automotive (<a href='https://seekingalpha.com/symbol/SAH' title='Sonic Automotive Inc.'>SAH</a> <font color='green'>+0.7%</font>) and CarMax (<a href='https://seekingalpha.com/symbol/KMX' title='CarMax Group'>KMX</a> <font color='green'>+0.1%</font>) are all higher.</li> <li>Auto suppliers Westport Fuel Systems (<a href='https://seekingalpha.com/symbol/WPRT' title='Westport Fuel Systems, Inc.'>WPRT</a> <font color='green'>+6.3%</font>), Workhorse Group (<a href='https://seekingalpha.com/symbol/WKHS' title='Workhorse Group Inc.'>WKHS</a> <font color='green'>+0.4%</font>), American Axle &amp; Manufacturing (<a href='https://seekingalpha.com/symbol/AXL' title='American Axle & Manufacturing Holdings, Inc.'>AXL</a> <font color='green'>+1.7%</font>), Stoneridge (<a href='https://seekingalpha.com/symbol/SRI' title='Stoneridge, Inc.'>SRI</a> <font color='green'>+1.4%</font>), Tenneco (<a href='https://seekingalpha.com/symbol/TEN' title='Tenneco Inc.'>TEN</a> <font color='green'>+0.6%</font>), Meritor (<a href='https://seekingalpha.com/symbol/MTOR' title='Meritor, Inc.'>MTOR</a> <font color='green'>+1.4%</font>) and Douglas Dynamics (<a href='https://seekingalpha.com/symbol/PLOW' title='Douglas Dynamics, Inc.'>PLOW</a> <font color='green'>+1.2%</font>) are also drawing attention.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3298984-truck-sales-dazzle-ford\" target=\"_blank\">Truck sales dazzle for Ford</a> (Oct. 3)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3298991-gm-rallies-topping-u-s-sales-estimates\" target=\"_blank\">GM rallies after topping U.S. sales estimates</a> (Oct. 3)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3298994-toyota-sails-past-u-s-sales-estimates\" target=\"_blank\">Toyota sails past U.S. sales estimates</a> (Oct. 3)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3298998-nissan-smashes-u-s-sales-estimates\" target=\"_blank\">Nissan smashes U.S. sales estimates</a> (Oct. 3)</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3299004\" data-linked=\"Automobile sector jolted by strong U.S. sales reports\" data-tweet=\"$CRMT $CRMT $AN - Automobile sector jolted by strong U.S. sales reports https://seekingalpha.com/news/3299004-automobile-sector-jolted-strong-u-s-sales-reports?source=tweet\" data-url=\"https://seekingalpha.com/news/3299004-automobile-sector-jolted-strong-u-s-sales-reports\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:03 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3299003\" data-ts=\"1507039347\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ERIC\" target=\"_blank\">ERIC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3299003-ericssonminus-2_4-credit-suisse-cuts-to-underperform\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Ericsson -2.4% as Credit Suisse cuts to Underperform</a></h4><ul>   <li>Ericsson (NASDAQ:<a href='https://seekingalpha.com/symbol/ERIC' title='LM Ericsson Telephone Company'>ERIC</a>) is <font color='red'>down 2.4%</font> in U.S. trading as Credit Suisse goes to an Underperform rating, with a downbeat view of the company's revenues and margins.</li>    <li>Sales might continue surprising on the downside, the firm says, and a medium-term target of more than 12% EBIT margin \"remains too optimistic\"; Credit Suisse expects a 5% margin for 2018 and a 7% margin for 2019.</li>    <li>It's lowered its price target to 38 kronor from 50, implying about 17% downside in the shares.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3299003\" data-linked=\"Ericsson -2.4% as Credit Suisse cuts to Underperform\" data-tweet=\"$ERIC - Ericsson -2.4% as Credit Suisse cuts to Underperform https://seekingalpha.com/news/3299003-ericssonminus-2_4-credit-suisse-cuts-to-underperform?source=tweet\" data-url=\"https://seekingalpha.com/news/3299003-ericssonminus-2_4-credit-suisse-cuts-to-underperform\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:02 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3298999\" data-ts=\"1507039134\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CYH\" target=\"_blank\">CYH</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3298999-community-health-under-modest-pressure-on-bearish-axios-report-shares-down-4\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Community Health under modest pressure on bearish Axios report; shares down 4%</a></h4><ul><li>Community Health Systems (<a href='https://seekingalpha.com/symbol/CYH' title='Community Health Systems, Inc.'>CYH</a> <font color='red'>-3.8%</font>) slips on light volume in apparent reaction to a <a href=\"https://www.axios.com/the-fuzzy-math-around-community-health-systems-hospital-sales-2491001792.html\" target=\"_blank\">report </a>by Axios that questions the veracity of the company's financial reporting and statements by executives, specifically the apparent disconnect between the multiple of divested hospitals with reported sales figures.</li></ul><div class=\"tiny-share-widget\" data-id=\"3298999\" data-linked=\"Community Health under modest pressure on bearish Axios report; shares down 4%\" data-tweet=\"$CYH - Community Health under modest pressure on bearish Axios report; shares down 4% https://seekingalpha.com/news/3298999-community-health-under-modest-pressure-on-bearish-axios-report-shares-down-4?source=tweet\" data-url=\"https://seekingalpha.com/news/3298999-community-health-under-modest-pressure-on-bearish-axios-report-shares-down-4\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:58 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3298994\" data-ts=\"1507038332\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TM\" target=\"_blank\">TM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3298994-toyota-sails-past-u-s-sales-estimates\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Toyota sails past U.S. sales estimates</a></h4><ul>     <li>Toyota (NYSE:<a href='https://seekingalpha.com/symbol/TM' title='Toyota Motor Corporation'>TM</a>) unit sales <a href=\"https://seekingalpha.com/pr/16958083-toyota-motor-north-america-reports-u-s-sales-september-first-nine-months-2017\" target=\"_blank\">+14.9%</a> to 226,632 units vs +10% forecast by Kelley Blue Book.</li> <li>Toyota division sales were up 16.9% to 200,436 units.</li> <li>Lexus division sales increased 1.5% to 26,196 units.</li> <li>Camry sales rose 13% to 34,732 units and Corolla sales were up 1.5% to 32,769. Demand was strong during the month for the RAV4 (+44%), Highlander (+36%) and 4Runner (+25%).</li>        <li>YTD Toyota U.S. sales +0.5% to 1,831,479 units.</li><li>Shares of Toyota are&nbsp;<font color='green'>up 0.36%</font>&nbsp;to $119.74.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3298994\" data-linked=\"Toyota sails past U.S. sales estimates\" data-tweet=\"$TM - Toyota sails past U.S. sales estimates https://seekingalpha.com/news/3298994-toyota-sails-past-u-s-sales-estimates?source=tweet\" data-url=\"https://seekingalpha.com/news/3298994-toyota-sails-past-u-s-sales-estimates\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:45 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3298993\" data-ts=\"1507038009\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/EXTR\" target=\"_blank\">EXTR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3298993-extreme-networksplus-5_6-after-forging-direct-purchase-deal-brocade\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Extreme Networks +5.6% after forging direct purchase deal with Brocade</a></h4><ul>   <li>Extreme Networks (NASDAQ:<a href='https://seekingalpha.com/symbol/EXTR' title='Extreme Networks, Inc.'>EXTR</a>) -- <a href=\"https://seekingalpha.com/news/3279352-broadcom-brocade-deal-delayed-allow-time-review\" target=\"_blank\">facing a delay</a> in its acquisition of the data center networking business of Brocade Communications (NASDAQ:<a href='https://seekingalpha.com/symbol/BRCD' title='Brocade Communications Systems, Inc.'>BRCD</a>) from Broadcom (<a href=\"http://seekingalpha.com/symbol/AVGO\" target=\"_blank\">AVGO</a> <font color='red'>-0.3%</font>) -- will now <a href=\"https://seekingalpha.com/pr/16957721-extreme-networks-acquire-data-center-business-directly-brocade-communications-systems\" target=\"_blank\">acquire the business directly</a> from Brocade.</li>    <li>Extreme shares have jumped out of the open, <font color='green'>up 5.6%</font>. Brocade has moved <font color='green'>up 1.2%</font>.</li>    <li>The new deal is at substantially the same terms as the previous deal. Extreme had expected to close its part of the deal within 2-3 days of a completed Broadcom/Brocade deal, which the companies expected to close during Brocade's Q4.</li><li>Brocade and Broadcom have extended their agreement and expect the acquisition to be completed by Nov. 30 (subject to CFIUS clearance).</li>    <li>\"We expect this agreement directly with Brocade to accelerate our ability to close our acquisition of the data center business,\" says Extreme CEO Ed Meyercord.</li>    <li>The company still expects the deal to be accretive to cash flow and earnings for fiscal 2018 and forecasts more than $230M in annualized revenue from the new assets.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3298993\" data-linked=\"Extreme Networks +5.6% after forging direct purchase deal with Brocade\" data-tweet=\"$EXTR $EXTR $BRCD - Extreme Networks +5.6% after forging direct purchase deal with Brocade https://seekingalpha.com/news/3298993-extreme-networksplus-5_6-after-forging-direct-purchase-deal-brocade?source=tweet\" data-url=\"https://seekingalpha.com/news/3298993-extreme-networksplus-5_6-after-forging-direct-purchase-deal-brocade\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:40 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3298991\" data-ts=\"1507037704\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GM\" target=\"_blank\">GM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3298991-gm-rallies-after-topping-u-s-sales-estimates\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">GM rallies after topping U.S. sales estimates</a></h4><ul>     <li>General Motors (NYSE:<a href='https://seekingalpha.com/symbol/GM' title='General Motors Company'>GM</a>) unit sales +11.9%</a> to 279,397 units in September vs. +8% forecast by Kelley Blue Book.</li><li>Sales by brand: Chevrolet +17% to 199,801 units; GMC +9% to 47,329; Buick -20% to 16,737; Cadillac +1% at 15,530.</li><li>Crossover deliveries jumped 43% during the month, with gains spread across brands.</li>    <li>GM ended the month with 76 days supply vs. 88 days at the end of August.</li> <li>Shares of GM <font color='green'>+3.51%</font> to $43.55.</li>   </ul><div class=\"tiny-share-widget\" data-id=\"3298991\" data-linked=\"GM rallies after topping U.S. sales estimates\" data-tweet=\"$GM - GM rallies after topping U.S. sales estimates https://seekingalpha.com/news/3298991-gm-rallies-after-topping-u-s-sales-estimates?source=tweet\" data-url=\"https://seekingalpha.com/news/3298991-gm-rallies-after-topping-u-s-sales-estimates\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:35 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>20&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3298984\" data-ts=\"1507037324\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/F\" target=\"_blank\">F</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3298984-truck-sales-dazzle-for-ford\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Truck sales dazzle for Ford</a></h4><ul>     <li>Ford (NYSE:<a href='https://seekingalpha.com/symbol/F' title='Ford Motor Company'>F</a>) unit sales <a href=\"https://seekingalpha.com/pr/16958090-ford-sales-8_7-percent-september-f-series-trucks-21_4-percent-transit-vans-gain-25_4-percent\" target=\"_blank\">+8.7%</a> to 222,248 vs. +3% estimated by Kelley Blue Book.</li>     <li>Passenger car sales -1.3% to 49,918 units.</li>     <li>SUV sales +1.8% to 68,705 units.</li>     <li>Truck sales +19.9% to 103,625 units.</li>     <li>YTD U.S. sales -2.8% to 1,933,459 units.</li> <li>Shares of Ford are&nbsp;<font color='green'>up&nbsp;2.56%</font>&nbsp;premarket to $12.40.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3298984\" data-linked=\"Truck sales dazzle for Ford\" data-tweet=\"$F - Truck sales dazzle for Ford https://seekingalpha.com/news/3298984-truck-sales-dazzle-for-ford?source=tweet\" data-url=\"https://seekingalpha.com/news/3298984-truck-sales-dazzle-for-ford\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:28 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>38&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3298983\" data-ts=\"1507037141\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PERI\" target=\"_blank\">PERI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3298983-perion-networkplus-4_4-creative-division-named-snapchat-partner\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Perion Network +4.4% as creative division named Snapchat partner</a></h4><ul>   <li>Perion Network (NASDAQ:<a href='https://seekingalpha.com/symbol/PERI' title='Perion Network Ltd.'>PERI</a>) is <font color='green'>up 4.4%</font> premarket after news that its creative ad division has been marked as an official <a href=\"https://seekingalpha.com/pr/16957439-perion-s-undertone-division-named-snapchat-creative-partner\" target=\"_blank\">Snapchat Creative Partner</a>.</li>    <li>The company's Undertone division received that designation.</li>    <li>Undertone has worked with brands like Unify Water and Niagara to take advantage of the features on Snapchat, Perion says.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3298983\" data-linked=\"Perion Network +4.4% as creative division named Snapchat partner\" data-tweet=\"$PERI - Perion Network +4.4% as creative division named Snapchat partner https://seekingalpha.com/news/3298983-perion-networkplus-4_4-creative-division-named-snapchat-partner?source=tweet\" data-url=\"https://seekingalpha.com/news/3298983-perion-networkplus-4_4-creative-division-named-snapchat-partner\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:25 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3298981\" data-ts=\"1507036788\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3298981-premarket-gainers-of-9-05\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket Gainers as of 9:05 am</a></h4><ul>     <li><a href='https://seekingalpha.com/symbol/ECYT' title='Endocyte, Inc.'>ECYT</a> <font color='green'>+60%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3298949-premarket-analyst-action-healthcare\" target=\"_blank\">positive</a> analyst action, extends rally.</li>     <li><a href='https://seekingalpha.com/symbol/VICL' title='Vical Incorporated'>VICL</a> <font color='green'>+39%</font>&nbsp;as mid-stage <a href=\"https://seekingalpha.com/news/3298856-mid-stage-study-may-suffice-lui-vicals-antifungal-vlminus-2397-shares-ahead-37-percent-hours\" target=\"_blank\">study</a> may suffice under LUI for Vical's antifungal VL-2397.</li>     <li><a href='https://seekingalpha.com/symbol/KOOL' title='Cesca Therapeutics Inc'>KOOL</a> <font color='green'>+25%</font>&nbsp;on U.S. patent <a href=\"https://seekingalpha.com/news/3298956-cesca-20-percent-premarket-u-s-patent-covering-car-txpress-platform\" target=\"_blank\">covering</a> CAR-TXpress platform.</li>     <li><a href='https://seekingalpha.com/symbol/CLSN' title='Celsion Corporation'>CLSN</a> <font color='green'>+25%</font>&nbsp;on final clinical and translational <a href=\"https://seekingalpha.com/pr/16958018-celsion-announces-final-clinical-translational-research-data-ovation-study-aacr-special\" target=\"_blank\">research data</a> from its OVATION Study.</li>     <li>ETRM <font color='green'>+23%</font>&nbsp;on <a href=\"https://seekingalpha.com/pr/16957781-enteromedics-announces-acquisition-reshape-medical\" target=\"_blank\">acquisition</a> of ReShape Medical.</li>     <li><a href='https://seekingalpha.com/symbol/TA' title='TravelCenters of America LLC'>TA</a> <font color='green'>+18%</font>.</li>     <li><a href='https://seekingalpha.com/symbol/CATB' title='Catabasis Pharmaceuticals'>CATB</a> <font color='green'>+8%</font>.</li>     <li><a href='https://seekingalpha.com/symbol/RIGL' title='Rigel Pharmaceuticals, Inc.'>RIGL</a> <font color='green'>+8%</font>&nbsp;on <a href=\"https://seekingalpha.com/pr/16957506-fostamatinib-meets-pre-specified-primary-endpoint-stage-1-autoimmune-hemolytic-anemia-aiha\" target=\"_blank\">completion</a> of enrollment of Stage 1 of its Phase 2, open-label, multi-center, two-stage study of its investigational drug fostamatinib for the treatment of patients with warm antibody AIHA.</li>     <li><a href='https://seekingalpha.com/symbol/ACRX' title='AcelRx Pharmaceuticals, Inc.'>ACRX</a> <font color='green'>+8%</font>.</li>     <li><a href='https://seekingalpha.com/symbol/ANY' title='Sphere 3D Corp.'>ANY</a> <font color='green'>+7%</font>.</li>     <li>ITUS <font color='green'>+7%</font>&nbsp;on <a href=\"https://seekingalpha.com/pr/16957363-itus-receives-notice-nasdaq-continued-listing-compliance\" target=\"_blank\">receiving</a> notice of nasdaq continued listing compliance.</li>     <li><a href='https://seekingalpha.com/symbol/DRYS' title='DryShips Inc.'>DRYS</a> <font color='green'>+7%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3298981\" data-linked=\"Premarket Gainers as of 9:05 am\" data-tweet=\"$ECYT $BBI $THMO - Premarket Gainers as of 9:05 am https://seekingalpha.com/news/3298981-premarket-gainers-of-9-05?source=tweet\" data-url=\"https://seekingalpha.com/news/3298981-premarket-gainers-of-9-05\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:19 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3298978\" data-ts=\"1507036639\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RSLS\" target=\"_blank\">RSLS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3298978-enteromedics-buys-reshape-medical-shares-ahead-30-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">EnteroMedics buys ReShape Medical; shares ahead 30% premarket</a></h4><ul><li>EnteroMedics (ETRM) is up&nbsp;<font color='green'>30%</font>&nbsp;premarket on robust volume on the heels of its <a href=\"https://seekingalpha.com/pr/16957781-enteromedics-announces-acquisition-reshape-medical\" target=\"_blank\">announced acquisition</a> of privately held <a href=\"https://reshapeready.com/\" target=\"_blank\">ReShape Medical</a>, the maker of the ReShape Dual Weight Loss Balloon for the treatment of obesity.</li><li>Under the terms of the agreement, ETRM will pay $5M in cash, 2,356,729 shares of common stock and 187,772 shares of series C convertible preferred stock that is convertible into 18,777,200 common shares if ETRM shareholders OK the deal. A special meeting will be scheduled by year-end.</li><li>Management will host a conference call this morning at 11:00 am ET to discuss the transaction.</li></ul><div class=\"tiny-share-widget\" data-id=\"3298978\" data-linked=\"EnteroMedics buys ReShape Medical; shares ahead 30% premarket\" data-tweet=\"$RSLS - EnteroMedics buys ReShape Medical; shares ahead 30% premarket https://seekingalpha.com/news/3298978-enteromedics-buys-reshape-medical-shares-ahead-30-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3298978-enteromedics-buys-reshape-medical-shares-ahead-30-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:17 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3298977\" data-ts=\"1507036614\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BB\" target=\"_blank\">BB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3298977-blackberry-will-transfer-to-nyse-on-october-16\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">BlackBerry will transfer to NYSE on October 16</a></h4><ul><li>        BlackBerry (BBRY) <a href=\"https://seekingalpha.com/pr/16957977-blackberry-announces-plan-move-new-york-stock-exchange\" target=\"_blank\">announces</a> its pending common stock transfer from Nasdaq to the New York Stock Exchange.</li><li>                  BlackBerry expects to start trading on the NYSE on October 16 under the ticker &ldquo;BB&rdquo;.    </li><li>               The company&rsquo;s TSX listing won&rsquo;t change. &nbsp;&nbsp;</li><li>               BlackBerry shares are&nbsp;<font color='green'>up 1.15%</font>&nbsp;premarket.&nbsp;&nbsp;&nbsp;&nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3298977\" data-linked=\"BlackBerry will transfer to NYSE on October 16\" data-tweet=\"$BB - BlackBerry will transfer to NYSE on October 16 https://seekingalpha.com/news/3298977-blackberry-will-transfer-to-nyse-on-october-16?source=tweet\" data-url=\"https://seekingalpha.com/news/3298977-blackberry-will-transfer-to-nyse-on-october-16\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:16 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>44&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3298975\" data-ts=\"1507036214\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3298975-premarket-losers-of-9-05\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket Losers as of 9:05 am</a></h4><ul>     <li><a href='https://seekingalpha.com/symbol/TTS' title='Tile Shop Holdings, Inc.'>TTS</a>&nbsp;<font color='red'>-33%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3298962-tile-shop-freefalls-sales-update-pulled-guidance\" target=\"_blank\">announcing</a> preliminary Q3 results.</li><li><a href='https://seekingalpha.com/symbol/RDHL' title='RedHill Biopharma Ltd.'>RDHL</a>&nbsp;<font color='red'>-5%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3298940-redhills-bekinda-shows-positive-effect-barely-mid-stage-ibs-d-study-shares-ease-3-percent\" target=\"_blank\">announcing</a> results from Phase II study of BEKINDA in patients with IBS-D.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3298975\" data-linked=\"Premarket Losers as of 9:05 am\" data-tweet=\"$TTSH $RDHL - Premarket Losers as of 9:05 am https://seekingalpha.com/news/3298975-premarket-losers-of-9-05?source=tweet\" data-url=\"https://seekingalpha.com/news/3298975-premarket-losers-of-9-05\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:10 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3298968\" data-ts=\"1507035511\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/INTU\" target=\"_blank\">INTU</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3298968-intuit-reaffirms-q1-fy18-outlooks-below-consensus\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Intuit reaffirms Q1, FY18 outlooks below consensus</a></h4><ul><li>        Intuit (NASDAQ:<a href='https://seekingalpha.com/symbol/INTU' title='Intuit Inc.'>INTU</a>) <a href=\"http://www.businesswire.com/news/home/20171003005849/en/Intuit-Hosts-Investor-Day-Reaffirms-First-quarter-Fiscal\" target=\"_blank\">reaffirms</a> its Q1 and FY18 guidance ahead of its Investor Day.</li><li>               Q1 outlook: $840M to $860M (consensus: $861.87M); Non-GAAP operating income, $15M to $25M; EPS, $0.03 to $0.05 (consensus: $0.05).&nbsp;</li><li>               FY18: revenue, $5.64B to $5.74B (consensus: $5.69B); Non-GAAP operating income, $1.885B to $1.935B; EPS, $4.90 to $5 (consensus: $4.95) ; QuickBooks Online subscribers, 3.275M to 3.375M.&nbsp;&nbsp;</li><li>Intuit shares are&nbsp;<font color='red'>down 1.11%</font>&nbsp;premarket.</li></ul><div class=\"tiny-share-widget\" data-id=\"3298968\" data-linked=\"Intuit reaffirms Q1, FY18 outlooks below consensus\" data-tweet=\"$INTU - Intuit reaffirms Q1, FY18 outlooks below consensus https://seekingalpha.com/news/3298968-intuit-reaffirms-q1-fy18-outlooks-below-consensus?source=tweet\" data-url=\"https://seekingalpha.com/news/3298968-intuit-reaffirms-q1-fy18-outlooks-below-consensus\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:58 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3298966\" data-ts=\"1507035086\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RARE\" target=\"_blank\">RARE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3298966-ultragenyx-to-acquire-dimension-therapeutics-for-6-share\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Ultragenyx to acquire Dimension Therapeutics for $6/share</a></h4><ul><li>Ultragenyx (NASDAQ:<a href='https://seekingalpha.com/symbol/RARE' title='Ultragenyx Pharmaceutical Inc.'>RARE</a>) <a href=\"https://seekingalpha.com/pr/16957788-ultragenyx-acquire-dimension-therapeutics\" target=\"_blank\">inks an agreement</a> to acquire Dimension Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/DMTX' title='Dimension Therapeutics'>DMTX</a>) for $151M, $6/share, in cash. RARE will fund the transaction with cash on hand.</li><li>DMTX is up&nbsp;<font color='green'>1%</font>&nbsp;premarket on light volume</li><li>Previously: <a href=\"https://seekingalpha.com/news/3298706-dimension-therapeutics-backs-ultragenyx-pharmas-6-share-bid-loser-regenxbio-get-2_85m\" target=\"_blank\">Dimension Therapeutics backs Ultragenyx Pharma's $6/share bid, loser REGENXBIO to get $2.85M termination fee</a> (Oct. 2)</li></ul><div class=\"tiny-share-widget\" data-id=\"3298966\" data-linked=\"Ultragenyx to acquire Dimension Therapeutics for $6/share\" data-tweet=\"$RARE $RARE $DMTX - Ultragenyx to acquire Dimension Therapeutics for $6/share https://seekingalpha.com/news/3298966-ultragenyx-to-acquire-dimension-therapeutics-for-6-share?source=tweet\" data-url=\"https://seekingalpha.com/news/3298966-ultragenyx-to-acquire-dimension-therapeutics-for-6-share\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:51 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3298965\" data-ts=\"1507035066\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TA\" target=\"_blank\">TA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3298965-convenience-store-stocks-on-watch-after-pilot-flying-j-buyout\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Convenience store stocks on watch after Pilot Flying J buyout</a></h4><ul> <li>TravelCenters of America (NYSEMKT:<a href='https://seekingalpha.com/symbol/TA' title='TravelCenters of America LLC'>TA</a>) is <font color='green'>up 21%</font> in premarket action after Berkshire Hathaway acquires Pilot Flying J.</li> <li>Keep an eye on Murphy USA (NYSE:<a href='https://seekingalpha.com/symbol/MUSA' title='Murphy USA, Inc.'>MUSA</a>) and Casey's General Stores (NASDAQ:<a href='https://seekingalpha.com/symbol/CASY' title='Casey&#39;s General Stores, Inc.'>CASY</a>) today to see if they catch similar action from investors.</li> <li>Previously: <a href=\"https://seekingalpha.com/news/3298946-berkshire-invest-pilot-flying-j\" target=\"_blank\">Berkshire to invest in Pilot Flying J</a> (Oct. 3)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3298965\" data-linked=\"Convenience store stocks on watch after Pilot Flying J buyout\" data-tweet=\"$TA $TA $MUSA - Convenience store stocks on watch after Pilot Flying J buyout https://seekingalpha.com/news/3298965-convenience-store-stocks-on-watch-after-pilot-flying-j-buyout?source=tweet\" data-url=\"https://seekingalpha.com/news/3298965-convenience-store-stocks-on-watch-after-pilot-flying-j-buyout\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:51 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>14&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3298964\" data-ts=\"1507034944\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SAND\" target=\"_blank\">SAND</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3298964-sandstorm-says-q3-gold-output-second-best-in-company-history\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Sandstorm says Q3 gold output second best in company history</a></h4><ul>     <li>Sandstorm Gold (NYSEMKT:<a href='https://seekingalpha.com/symbol/SAND' title='Sandstorm Gold Ltd.'>SAND</a>)&nbsp;<font color='green'>+2.1%</font> premarket after saying it sold 14,290 gold equiv. oz. during Q3, the <a href=\"https://seekingalpha.com/pr/16956983-sandstorm-gold-announces-third-quarter-production-numbers-provides-asset-updates\" target=\"_blank\">second highest quarterly total</a> in the company's history.</li>     <li>SAND says it has sold ~42.6K gold equiv. oz. YTD, consistent with its full-year forecast of 50K-55K gold equiv. oz.</li>     <li>SAND forecasts attributable gold equiv. production of 130K oz./year by 2022.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3298964\" data-linked=\"Sandstorm says Q3 gold output second best in company history\" data-tweet=\"$SAND - Sandstorm says Q3 gold output second best in company history https://seekingalpha.com/news/3298964-sandstorm-says-q3-gold-output-second-best-in-company-history?source=tweet\" data-url=\"https://seekingalpha.com/news/3298964-sandstorm-says-q3-gold-output-second-best-in-company-history\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:49 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>43&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3298962\" data-ts=\"1507034252\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TTS\" target=\"_blank\">TTS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3298962-tile-shop-freefalls-after-sales-update-pulled-guidance\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Tile Shop freefalls after sales update, pulled guidance</a></h4><ul> <li>The Tile Shop (NASDAQ:<a href='https://seekingalpha.com/symbol/TTS' title='Tile Shop Holdings, Inc.'>TTS</a>) releases <a href=\"https://seekingalpha.com/pr/16957144-tile-shop-announces-preliminary-third-quarter-2017-results-announces-third-quarter-2017\" target=\"_blank\">Q3 sales numbers</a> on a preliminary basis.</li> <li>The company says it expects to report sales rose 7% to $84M vs. $87M consensus. Comparable store sales growth is anticipated to be 5.7%.</li> <li>Tile Shop expects to report gross margin of 66% to 67% of sales for the quarter vs. 70% consensus.</li> <li>\"A more competitive environment led to weaker than expected results in our third quarter,\" says CEO Chris Homeister.</li> <li>The company states that prior expectations for the full year are now off the table, but didn't add any updated guidance.</li> <li>Tile Shop is also taking on a biting <a href=\"https://www.streetinsider.com/Analyst+PT+Change/Telsey+Downgrades+Tile+Shop+Holdings+%28TTS%29+to+Underperform/13352182.html\" target=\"_blank\">downgrade</a> from Telsey today. The firm warns on a trend of decelerating profit. It's likely to be the first of many downgrades.</li> <li>Shares are <font color='red'>down 32.58%</font> premarket to $8.90.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3298962\" data-linked=\"Tile Shop freefalls after sales update, pulled guidance\" data-tweet=\"$TTS $TTSH - Tile Shop freefalls after sales update, pulled guidance https://seekingalpha.com/news/3298962-tile-shop-freefalls-after-sales-update-pulled-guidance?source=tweet\" data-url=\"https://seekingalpha.com/news/3298962-tile-shop-freefalls-after-sales-update-pulled-guidance\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:37 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>10&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3298960\" data-ts=\"1507034102\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BHC\" target=\"_blank\">BHC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3298960-valeants-b-l-launches-new-biotrue-oneday-contact-lens-in-europe\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Valeant&#39;s B+L launches new Biotrue ONEday contact lens in Europe</a></h4><ul><li>Valeant Pharmaceutical's (VRX) Bausch + Lomb unit <a href=\"https://seekingalpha.com/pr/16957650-bausch-lomb-introduces-biotrue-oneday-astigmatism-contact-lenses-europe\" target=\"_blank\">launches </a>its Biotrue ONEday for Astigmatism daily disposable contact lenses in 20 European countries. The company says the product has a peri-ballast design for stability and a unique dehydration barrier that helps the lens maintain 98% of its moisture for up to 16 hours.</li><li>Shares are up&nbsp;<font color='green'>1%</font>&nbsp;premarket on light volume.</li></ul><div class=\"tiny-share-widget\" data-id=\"3298960\" data-linked=\"Valeant&#39;s B+L launches new Biotrue ONEday contact lens in Europe\" data-tweet=\"$BHC - Valeant&#39;s B+L launches new Biotrue ONEday contact lens in Europe https://seekingalpha.com/news/3298960-valeants-b-l-launches-new-biotrue-oneday-contact-lens-in-europe?source=tweet\" data-url=\"https://seekingalpha.com/news/3298960-valeants-b-l-launches-new-biotrue-oneday-contact-lens-in-europe\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:35 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>10&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3298959\" data-ts=\"1507034094\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PAYX\" target=\"_blank\">PAYX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3298959-paychex-beats-0_02-misses-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Paychex beats by $0.02, misses on revenue</a></h4><ul><li>Paychex (NASDAQ:<a href='https://seekingalpha.com/symbol/PAYX' title='Paychex, Inc.'>PAYX</a>): Q1 EPS of $0.62 <font color='green'>beats by $0.02</font>.</li><li>Revenue of $816.8M (+4.0% Y/Y) <font color='red'>misses by $3.78M</font>.</li><li>Shares <font color='green'>+2.66%</font> PM.</li><li><a href='https://seekingalpha.com/pr/16957766-paychex-inc-reports-first-quarter-results'>Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3298959\" data-linked=\"Paychex beats by $0.02, misses on revenue\" data-tweet=\"$PAYX - Paychex beats by $0.02, misses on revenue https://seekingalpha.com/news/3298959-paychex-beats-0_02-misses-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3298959-paychex-beats-0_02-misses-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:34 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3298956\" data-ts=\"1507033589\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/KOOL\" target=\"_blank\">KOOL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3298956-cesca-up-20-premarket-on-u-s-patent-covering-car-txpress-platform\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Cesca up 20% premarket on U.S. patent covering CAR-TXpress platform</a></h4><ul><li>Thinly traded nano cap Cesca Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/KOOL' title='Cesca Therapeutics Inc'>KOOL</a>) jumps&nbsp;<font color='green'>20%</font>&nbsp;premarket on increased volume in response to its <a href=\"https://seekingalpha.com/pr/16957465-cesca-receives-notice-allowance-u-s-patent-application-covering-novel-method-cell-separation\" target=\"_blank\">announcement </a>that the USPTO has issued a Notice of Allowance for its patent application covering its cell separation technology called BACS (Buoyancy-Activated Cell Separation) which it says is essential to the ongoing development of its CAR-TXpress platform.</li><li>The patent, when issued, will be second covering the technology.</li></ul><div class=\"tiny-share-widget\" data-id=\"3298956\" data-linked=\"Cesca up 20% premarket on U.S. patent covering CAR-TXpress platform\" data-tweet=\"$KOOL $THMO - Cesca up 20% premarket on U.S. patent covering CAR-TXpress platform https://seekingalpha.com/news/3298956-cesca-up-20-premarket-on-u-s-patent-covering-car-txpress-platform?source=tweet\" data-url=\"https://seekingalpha.com/news/3298956-cesca-up-20-premarket-on-u-s-patent-covering-car-txpress-platform\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:26 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3298955\" data-ts=\"1507033573\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CAMT\" target=\"_blank\">CAMT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3298955-needham-co-upgrades-camtek\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Needham &amp; Co. upgrades Camtek</a></h4><ul><li>        Needham &amp; Company <a href=\"https://www.streetinsider.com/Analyst+Comments/UPDATE%3A+Needham+%26+Company+Upgrades+Camtek+%28CAMT%29+to+Buy/13352241.html\" target=\"_blank\">upgrades</a> Camtek (NASDAQ:<a href='https://seekingalpha.com/symbol/CAMT' title='Camtek Ltd.'>CAMT</a>) from Hold to Buy with a $7 price target.</li><li>               Analyst Edwin Mok cites the divestiture of Camtek's PCB business as streamlining the company and expects peer outperformance into next year.&nbsp;</li><li>Camtek shares are&nbsp;<font color='green'>up 3.14%</font>&nbsp;premarket.&nbsp;&nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3298955\" data-linked=\"Needham &amp; Co. upgrades Camtek\" data-tweet=\"$CAMT - Needham &amp; Co. upgrades Camtek https://seekingalpha.com/news/3298955-needham-co-upgrades-camtek?source=tweet\" data-url=\"https://seekingalpha.com/news/3298955-needham-co-upgrades-camtek\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:26 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3298949\" data-ts=\"1507032811\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/WST\" target=\"_blank\">WST</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3298949-premarket-analyst-action-healthcare\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket analyst action - healthcare</a></h4><ul><li>West Pharmaceutical Services (NYSE:<a href='https://seekingalpha.com/symbol/WST' title='West Pharmaceutical Services Inc.'>WST</a>) initiated with Equal Weight rating and $99 (2% upside) price target by Stephens.</li><li>Endocyte (NASDAQ:<a href='https://seekingalpha.com/symbol/ECYT' title='Endocyte, Inc.'>ECYT</a>) upgraded to Outperform with a $7 (93% upside) by Wedbush after license deal for prostate cancer candidate.</li><li>Exact Sciences (NASDAQ:<a href='https://seekingalpha.com/symbol/EXAS' title='EXACT Sciences Corporation'>EXAS</a>) price target raised to street-high $60 (25% upside) by Canaccord Genuity based on bullish reorder rates for Cologuard test.</li><li>Sucampo (NASDAQ:<a href='https://seekingalpha.com/symbol/SCMP' title='Sucampo Pharmaceuticals, Inc.'>SCMP</a>) downgraded to Neutral with a $12 (flat) price target by Mizuho Securities.</li><li>Biohaven Pharmaceutical (NYSE:<a href='https://seekingalpha.com/symbol/BHVN' title='Biohaven Pharmaceutical Holding Company Ltd.'>BHVN</a>) price target cut to $36 (8% downside risk) from $43 by Needham after Phase 2/3 study of trigriluzole in spinocerebellar ataxia failed to beat placebo.</li><li>Source: Bloomberg</li></ul><div class=\"tiny-share-widget\" data-id=\"3298949\" data-linked=\"Premarket analyst action - healthcare\" data-tweet=\"$WST $WST $ECYT - Premarket analyst action - healthcare https://seekingalpha.com/news/3298949-premarket-analyst-action-healthcare?source=tweet\" data-url=\"https://seekingalpha.com/news/3298949-premarket-analyst-action-healthcare\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:13 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3298940\" data-ts=\"1507031828\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RDHL\" target=\"_blank\">RDHL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3298940-redhills-bekinda-shows-positive-effect-barely-in-mid-stage-ibs-d-study-shares-ease-3\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">RedHill&#39;s Bekinda shows positive effect (barely) in mid-stage IBS-D study; shares ease 3% premarket</a></h4><ul><li>RedHill Biopharma (NASDAQ:<a href='https://seekingalpha.com/symbol/RDHL' title='RedHill Biopharma Ltd.'>RDHL</a>) <a href=\"https://seekingalpha.com/pr/16957471-redhill-biopharma-announces-positive-top-line-results-phase-ii-study-bekinda-patients\" target=\"_blank\">announces </a>positive results from a 51-subject Phase 2 clinical trial assessing BEKINDA (ondansetron) 12 mg in patients with diarrhea-predominant irritable bowel syndrome (IBS-D).</li><li>The study met its primary endpoint of demonstrating a statistically significant proportion of stool consistency responders in the treatment group versus placebo (54.7% vs. 35.3%; p=0.05).</li><li>The company says the absolute difference of 19.4% compares favorably with two Phase 3 studies of Salix Pharmaceuticals' (VRX) Xifaxan (rifaximin) 550 mg (10.5%) and two Phase 3s of Allergan's (NYSE:<a href='https://seekingalpha.com/symbol/AGN' title='Allergan plc'>AGN</a>) Viberzi (eluxadoline) 100 mg (13.5%), but the results were not statistically significant (p=0.28).</li><li>The overall response rate difference between BEKINDA and placebo (15.8%) also compared favorably with Xifaxan (9.5%) and Viberzi (10.5%) but the results were (again)&nbsp;not statistically significant (p=0.10), as were the rest of the secondary endpoints, but the company says the study was not powered to demonstrate statistical validity on these metrics.</li><li>BEKINDA was shown to be safe and well-tolerated.</li><li>Detailed results will be submitted for presentation at future medical conferences.</li><li>The company intends to advance BEKINDA into Phase 3 development. It plans to meet with the FDA in Q1 2018 to clarify a path to U.S. approval. If the first Phase 3 study is successful, it will design a Phase 3 study in acute gastroenteritis and gastritis to support a U.S. marketing application for that indication.</li><li>Management will host a conference call today at 9:00 am ET to discuss the results.</li><li>Shares are down&nbsp;<font color='red'>3%</font>&nbsp;premarket on increased volume as investors appear underwhelmed with the results.</li></ul><div class=\"tiny-share-widget\" data-id=\"3298940\" data-linked=\"RedHill&#39;s Bekinda shows positive effect (barely) in mid-stage IBS-D study; shares ease 3% premarket\" data-tweet=\"$RDHL $RDHL $BHC - RedHill&#39;s Bekinda shows positive effect (barely) in mid-stage IBS-D study; shares ease 3% premarket https://seekingalpha.com/news/3298940-redhills-bekinda-shows-positive-effect-barely-in-mid-stage-ibs-d-study-shares-ease-3?source=tweet\" data-url=\"https://seekingalpha.com/news/3298940-redhills-bekinda-shows-positive-effect-barely-in-mid-stage-ibs-d-study-shares-ease-3\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:57 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>54&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3298924\" data-ts=\"1507029156\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HLF\" target=\"_blank\">HLF</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3298924-herbalife-launches-self-tender-for-up-to-600m-of-common-stock-ups-q3-earnings-guidance\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Herbalife launches self-tender for up to $600M of common stock; ups Q3 earnings guidance</a></h4><ul><li>Herbalife (NYSE:<a href='https://seekingalpha.com/symbol/HLF' title='Herbalife Ltd.'>HLF</a>) <a href=\"https://seekingalpha.com/pr/16957168-part-herbalife-nutrition-s-self-tender-offer-company-updates-guidance-third-quarter-2017\" target=\"_blank\">commences </a>its modified Dutch auction self-tender offer to purchase up to $600M of its common shares for $60 - 68. Sellers will receive one non-transferable contractual contingent value right &#40;CVR&#41; for each share sold that allows them to receive a contingent cash payment in the event that the company is acquired in a go-private transaction within two years of the start of the tender offer.</li><li>The self-tender offer will expire at 5:00 pm ET on Thursday, October 5.</li><li>Concurrently, the company updates its Q3 guidance:</li><li>Volume point growth: (6.0% - 4.8%) from (7.0% - 2.0%); Net sales growth: (3.4% - 1.9%) from (5.0%) - 0.0%; EPS: $0.63 - 0.73 from $0.48 - 0.68; Non-GAAP EPS: $0.80 - 0.90 from $0.65 - 0.85; Currency-adjusted EPS: $0.84 - 0.94 from $0.70 - 0.90.</li></ul><div class=\"tiny-share-widget\" data-id=\"3298924\" data-linked=\"Herbalife launches self-tender for up to $600M of common stock; ups Q3 earnings guidance\" data-tweet=\"$HLF - Herbalife launches self-tender for up to $600M of common stock; ups Q3 earnings guidance https://seekingalpha.com/news/3298924-herbalife-launches-self-tender-for-up-to-600m-of-common-stock-ups-q3-earnings-guidance?source=tweet\" data-url=\"https://seekingalpha.com/news/3298924-herbalife-launches-self-tender-for-up-to-600m-of-common-stock-ups-q3-earnings-guidance\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:12 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>64&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3298918\" data-ts=\"1507028335\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ZGNX\" target=\"_blank\">ZGNX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3298918-zogenix-prices-stock-offering-37_50\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Zogenix prices stock offering at $37.50</a></h4><ul><li>Zogenix (NASDAQ:<a href='https://seekingalpha.com/symbol/ZGNX' title='Zogenix, Inc.'>ZGNX</a>) <a href=\"https://seekingalpha.com/pr/16957246-zogenix-prices-public-offering-common-stock\" target=\"_blank\">prices </a>its public offering of 6.7M shares of common stock at $37.50 per share. Underwriters over-allotment is an additional 1.005M shares. Closing date is October 5. Net proceeds will fund the development of ZX008, working capital and general corporate purposes.</li><li>Yesterday's close was $38.90.</li></ul><div class=\"tiny-share-widget\" data-id=\"3298918\" data-linked=\"Zogenix prices stock offering at $37.50\" data-tweet=\"$ZGNX - Zogenix prices stock offering at $37.50 https://seekingalpha.com/news/3298918-zogenix-prices-stock-offering-37_50?source=tweet\" data-url=\"https://seekingalpha.com/news/3298918-zogenix-prices-stock-offering-37_50\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:58 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li>","count":73,"message":null,"success":true,"today":{"start":1577077200,"end":1577163599,"str":"Monday, December 23, 2019"},"yesterday":{"start":1576990800,"end":1577077199}}